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For the last two decades, our research group has focused on developing 
nanotechnology-based diagnostic platforms for disease detection. One of our main 
diagnostic platforms is magnetic immunoassay based on giant magnetoresistance (GMR) 
readout. Due to high sensitivity and rapid data retrieval of the GMR readout, GMR-based 
immunoassays enable a low level of rapid detection of disease markers and have the 
potential for multiplexing (i.e., detecting multiple analytes simultaneously). As part of an 
effort to develop a GMR-based multiplexing test, this dissertation focuses on the 
development of magnetic labels for use in magnetic immunoassays. Thus, the body of this 
dissertation includes: (1) synthesis of magnetic nanoparticles (MNPs) with high magnetic 
moments; (2) emulsion-based bottom-up assembly approach to design new magnetic 
materials; (3) surface functionalization of MNPs and biomolecule conjugation for use as 
magnetic labels; and (4) development of magnetic immunoassays for the detection of 
potential pancreatic cancer markers using our GMR sensor. 
Firstly, silica encapsulation of ferrimagnetic nanocubes with high magnetic 
moments (m) is described. These results not only demonstrate the synthesis of high-m 
MNPs uniform in size and shape, but also stabilization of the MNPs with high m via silica 
coating. Secondly, the fabrication of colloidal assembly of MNPs is discussed with the 





a larger magnetic bead can not only change their magnetic properties, but also be an 
efficient way to design new materials for specific applications. Next, surface coating and 
biomolecule conjugation of the colloidally assembled magnetic beads are investigated to 
prepare magnetic labels. These results indicate that magnetic labels based on colloidally 
assembled magnetic beads are superior to commercially available magnetic labels. The last 
chapter is focused on the development of magnetic immunoassays for the simultaneous 
detection of pancreatic cancer markers based on our magnetic label and GMR sensor. The 
results show the potential of a GMR-based diagnostic platform in rapid and sensitive 
detection of disease marker, as well as multiplexing. With these results, this dissertation 
aims to the development of magnetic labels for GMR-based magnetic immunoassays 
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Fe(acac)3 ............................................................................................... iron acetylacetonate 
FITC ............................................................................................. fluorescein isothiocyanate 





γ-Fe2O3 ................................................................................................................. maghemite 
GMR ............................................................................................... giant magnetoresistance 
ħ......................................................................................................reduced Plank’s constant 
H .....................................................................................................................magnetic field 
Happ .................................................................................................... applied magnetic field 
Hc ...........................................................................................................................coercivity 
ICDD ....................................................................... international center for diffraction data 
ICP-MS ....................................................... inductively coupled plasma mass spectroscopy 
IOMB ............................................................................................ iron oxide magnetic bead 
IOMB@PVP .................................. polyvinylpyrrolidone-coated iron oxide magnetic bead 
IONP ................................................................................................ iron oxide nanoparticle 
IR......................................................................................................... infrared spectroscopy 
IRM ............................................................................... isothermal remanent magnetization 
kB ............................................................................................................ Boltzmann constant 
K ............................................................................................................. anisotropy constant 
K .................................................................................................................................. Kelvin 
LbL .................................................................................................................. layer-by-layer 
LoD ............................................................................................................ limit of detection 
µB ................................................................................................................... Bohr magneton 
µMBs .................................................................................................................... microbead 
mparticle .................................................................................... magnetic moment per particle 
m ............................................................................................................... magnetic moment 
M ..................................................................................................................... magnetization 
Ms ................................................................................................... saturation magnetization 
Mr .................................................................................................... remanent magnetization 
MES ........................................................................... 2-(N-morpholino)ethanesulfonic acid 
MR ........................................................................................................... magnetoresistance 
MMP-7 ....................................................................................... matrix metalloproteinase-7 
MNP ................................................................................................... magnetic nanoparticle 
MRE ...................................................................................... molecular recognition element 
MWCO ............................................................................................ molecular weight cutoff 
NaCl ............................................................................................................. sodium chloride 
NCCN .................................................................... national comprehensive cancer network 
NH4OH ............................................................................................... ammonium hydroxide 
NIH .............................................................................................. national institute of health 
OPN..................................................................................................................... osteopontin 
pM ......................................................................................................................... picomolar 
PAA.............................................................................................................. polyacrylic acid 
PAAm ...........................................................................................................polyallyl amine 
PBS .............................................................................................. phosphate-buffered saline 
PDAC .............................................................................. pancreatic ductal adenocarcinoma 
PEI............................................................................................................ polyethyleneimine 
PSS ...................................................................................................... polystyrene sulfonate 
PVA........................................................................................................... polyvinyl alcohol 
PVP ......................................................................................................polyvinylpyrrolidone 





rh ............................................................................................................ recombinant human 
σ ......................................................................................................... specific magnetization 
S ......................................................................................................................... surface area 
SEM ....................................................................................... scanning electron microscopy 
SPMNP ...............................................................................superparamagnetic nanoparticle 
sulfo-NHS ................................................................................. N-hydroxysuflosuccinimide 
θ ..................................................................................................................................... angle 
T ......................................................................................................................... temperature 
TB ......................................................................................................... blocking temperature 
TEM ................................................................................. transmission electron microscopy 
TIMP-1 ...................................................................... tissue inhibitor of metalloproteinase 1 
UE .................................................................................................... electrophoretic mobility 
V .................................................................................................................................volume 
VSM .................................................................................... vibrating sample magnetometry 
χirr .................................................................................................. irreversible susceptibility 
XRD ........................................................................................................... X-ray diffraction 
ζ-potential......................................................................................................... zeta-potential 
ZFC/FC .................................................................................. zero-field cooled/field cooled 
ZFNC ................................................................................................... zinc ferrite nanocube 
ZFNC@SiO2 ................................................................... silica-coated zinc ferrite nanocube 
ZFMB ........................................................................................... zinc ferrite magnetic bead 
ZFMB@PVP ................................. polyvinylpyrrolidone-coated zinc ferrite magnetic bead 
ZFMB@PVP@PAA ............................. polyacrylic acid-coated zinc ferrite magnetic bead 
ZFMB@PVP@PAA@SA ................................ streptavidinated zinc ferrite magnetic bead 
ZFNP ............................................................................................... zinc ferrite nanoparticle 
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Early detection of cancer is an important strategy for public health. Frequently, 
early diagnosis of cancer increases the chances for effective treatment, which can improve 
outcomes and/or increase the life expectancy/quality of a patient after the treatment. 
Diagnosis of cancer in its early stage requires screening of a healthy population and the 
recognition of disease markers early in disease progression. In the first stages of cancer, a 
number of markers indicative of a cancer can be present and the level of the cancer markers 
present in a patient sample is usually low. Therefore, a diagnostic tool capable of 
simultaneous detection of multiple disease markers as well as with a high analytical 
sensitivity is required for early diagnosis of cancer. 
One of the most common in-vitro diagnostic testing platforms for disease diagnosis 
is the solid-phase immunoassay. Solid-phase immunoassays utilize the selective and 
specific targeting function of antibodies to antigens that indicate the presence of a disease. 
However, these immunoassays are often designed to detect a single analyte and, as a 
consequence, can require a large sample volume and extensive labor in order to 





increase in test costs. In addition, the existing solid-phase immunoassays usually require 
sophisticated instrumentation and highly skilled technicians, both of which can prove 
challenging in resource-limited settings. Therefore, the development of immunoassays 
with a high sensitivity, low cost, and multiplexing capability is of great interest in the 
bioanalytical arena and clinical diagnostics.  
Giant-magnetoresistive (GMR) sensors, which had been used as a readout 
mechanism in computer hard drives, are small, sensitive, and have high read rates. The last 
decade has seen a large growth in the use of GMR sensors as a quantitative tool for disease 
detection by combining immunoassays with magnetic labels. In this vein, this dissertation 
describes the development of a GMR-based diagnostic tool for the detection of potential 
pancreatic cancer markers. The work presented includes: (1) the preparation of new types 
of magnetic labels, and (2) the development of multiplexed immunoassays for the detection 
of potential pancreatic cancer markers by using these magnetic labels.  
This Introduction provides background materials relate to the topics addressed 
throughout the dissertation, including solid-phase immunoassays, magnetic nanoparticles, 
magnetism, GMR sensors, and pancreatic cancer. The main body of this dissertation 
consists of four original research chapters. Chapter 2 describes a method to deposit a 
uniform silica layer on ferrimagnetic zinc ferrite nanocubes enabled layer-by-layer 
deposition of polyelectrolyte. The results of magnetic characterizations in each synthesis 
step are also presented. Chapter 3 investigates the magnetic properties of colloidally 
assembled zinc ferrite magnetic beads. Chapter 4 discusses the synthetic procedures used 
to build magnetic labels based on colloidally assembled magnetic beads and their 





magnetic labels developed in Chapter 4 in the simultaneous detection of potential 
pancreatic cancer markers in buffer and serum. This dissertation concludes with a 
perspective on potential importance of development and optimization of magnetic labels 
for solid-phase immunoassays and on future directions in the early diagnosis of pancreatic 
cancer based on solid-phase immunoassays and GMR sensors. 
 
1.2 Solid-phase Immunoassays 
In the 1930s, Heidelberger and colleagues made major contributions to 
immunochemical studies of antigen-antibody reactions.1-4 They showed that antigen-
antibody reactions take place in accordance with a set of predictable rules grounded in 
biochemical interactions. They also demonstrated that the quantity of antigen in a sample 
can be accurately determined by using an antigen-antibody reaction. These principles 
received tremendous attention and allowed the use of antigen-antibody binding as 
quantitative tools in immunochemistry and clinical chemistry. 
The work by Yalow, Berson, and Ekins in the late 1950s opened up the age of 
radioimmunoassays.5-6 The first radioimmunoassay used a competitive format, in which 
the analyte of interest and a radioisotope-labeled derivative of the analyte were mixed and 
applied to a finite amount of antibody. As the concentration of the analyte increases, more 
of the analyte binds to the antibody, decreasing the ratio of antibody-bound radioisotope-
labeled analyte to free radioisotope-labeled analyte. Then, the radioactivity of the unbound 
analyte in the supernatant is used to quantify analyte concentration in the sample. 
Competitive binding is concentration dependent and the signal output is inversely 





Since then, there has been a number of significant improvements in assay 
configuration, reagents, and detection tools. The development of monoclonal antibody 
production allowed new immunoassay designs with improved sensitivity and specificity.7 
The first two-site immunoassay (i.e., sandwich immunoassay) was introduced in 1971.8 A 
schematic illustration of a sandwich immunoassay is shown in Figure 1.1. In this assay, 
capture antibodies are tethered on a surface via adsorption or covalent bonding. In the next 
steps, analytes specific to the capture antibody bind to the capture antibodies, and 
secondary antibodies, which may or may not be modified with a label for signal 
transduction, tag the bound analytes. Finally, the response from the surface-bound labels 
is used in quantitative analysis of analyte-antibody binding events.  
Efforts to replace radioisotopic materials with alternatives have been made to avoid 
possible health risks, stability problems, and other difficulties in handling radioisotopes. 
Alternatives include enzymatic labels with chromogenic and fluorogenic substrates,9 and 
fluorescent, chemiluminescent, and bioluminescent molecules.10-12 The utilization of other 




Figure 1.1 Schematic diagram for a sandwich immunoassay: (1) analyte binding to capture 





Immunoassays with colorimetric readout method, e.g. enzyme-linked 
immunosorbent assay (ELISA), are the gold standard in today’s in-vitro diagnostics arena. 
However, nanotechnology-based detection methods and nanoparticle labels have begun to 
meet the demand for diagnostic tools with a high speed, sensitivity, improved levels of 
detection, and higher throughput. Single-molecule enzyme-linked immunosorbent assay 
(a.k.a., digital ELISA) can detect single protein molecules at sub-femtomolar 
concentrations.13 Immunoassays using surface-enhanced Raman scattering readout and 
gold nanoparticle labels have also redefined detection.14-16 Giant-magnetoresistive sensors 
use magnetic nanoparticles as labels and are a promising alternative for the simultaneous 
detection of multiple markers with low analytical sensitivity.17-18 Emission-based detection 
is highly sensitive and takes advantage of the photostability and narrow emission bands of 
quantum dot and lanthanide-derived nanoparticle labels. The more traditional organic dye 
labels in assays suffer from photobleaching and broad emission bands which can hinder 
their usage in multiplexed assays.19 Each of these techniques exhibits great promise for the 
next generation of diagnostic technologies for use in clinical, environmental, and food 
testing arenas. 
The last few decades have witnessed a number of breakthroughs in the field of 
immunoassays regarding assay configuration, labeling strategies, and new instrumentation. 
Some on-going and future efforts in this area include the development of: (1) preanalytical 
treatments for the detection of analytes in serum and patient samples; (2) multiplexed 
immunoassays for the detection of a panel of analytes; (3) biosensors suitable for use in 
field-deployable settings and chip-scale detection; and (4) assays with even lower limits of 





immunoassays will continue to be developed and be used as in-vitro diagnostic tools in the 
coming decades. 
 
1.3 Synthesis of Magnetic Nanoparticles 
Magnetic nanoparticles (MNPs) are a class of nanoparticle that can be manipulated 
by an external magnetic field. Numerous MNPs have been synthesized with a range of 
composition, like iron oxides (Fe3O4 and γ-Fe2O3), ferrites (MgxFe3-xO4, ZnxFe3-xO4, and 
CoxFe3-xO4), metals (Fe and Co), and metal alloys (FePt, NiCo, and FeCo).20 There are a 
few popular synthetic methods for producing MNPs, including coprecipitation,21 thermal 
decomposition,22 hydrothermal synthesis,23 and microemulsion.24 These methods have 
been developed and fine-tuned in order to generate MNPs with high magnetic moments as 
well as a high level of uniformity in size and shape. Table 1.1 lists the advantages and 
disadvantages of the different synthetic routes. At present, MNPs prepared using 
coprecipitation and thermal decomposition have been the most extensively studied of the 
materials, both at a fundamental level as several types of applications. The microemulsion 
method can also produce MNPs with different morphologies, but is not as scalable as other 
routes. While hydrothermal and gas-phase methods have not been heavily explored, those 
routes can potentially be effective methods for the synthesis of high-quality MNPs. To 
date, thermal decomposition has proven to be the best option to synthesize MNPs uniform 
in size and shape. Thermal decomposition enables the synthesis of MNPs with excellent 
control over size and shape (a standard deviation of size typically less than 10%). With 
thermal decomposition (Figure 1.2A), MNPs are synthesized by decomposing organo-
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Figure 1.2 Synthesis of MNPs. (A) Schematic illustration of thermal decomposition. (B) 
Electron micrographs of zinc ferrite nanoparticles synthesized via thermal 
decomposition: (i) spherical and (ii-iv) cubic MNPs of different sizes. 
 
high temperature (250 – 350 °C), as shown in Figure 1.2A. Organo-metallic precursors 
include metal acetylacetonates [M(acac)n; M = Fe, Mn, Co, Zn, and Ni; n = 2 or 3] and 
metal carbonyls (e.g., Fe(CO)5 and Co2(CO)8). Fatty acids and hydrocarbons with terminal 
groups (e.g., carboxylic acids and amines) are often used as surface-capping agents. 
Because of the long hydrocarbon chains in the surface-capping agents, the as-synthesized 
MNPs can only be dispersed in nonpolar solvents. As shown in Figure 1.2, MNPs with 
different sizes and shapes can be produced by changing precursors, solvents, and/or 
surface-capping agents. These materials must then be surface modified to meet the 





1.4 Concepts in Magnetism and Measurement of Magnetic Parameters 
There are several different systems currently used to define magnetic quantities. 
Table 1.2 summarizes cgs and SI systems. One of the most fundamental concepts in 
magnetism is a magnetic field (H). H is generated when an electrical charge is in motion. 
H at any given point is represented by a vector field, which has both a direction and a 
strength. When H is produced in a volume of space, there is an energy gradient in the 
volume and, therefore, a force is produced. This force can be detected by the torque on a 
magnetic dipole like a bar magnet. The magnetic moment (m) of a magnet or electron 
equals the torque applied on the magnet or electron by an external H. Consider two bar 
magnets adjacent to each other. The total m of the two magnets is the vector sum of 
magnetic moments of the individual magnets. In this case, the total m is doubled by an 
increase in the volume (V). However, the m per volume has not changed. This volume-







Table 1.2 Unit systems in magnetism. 
Quantity Symbol cgs SI Conversion factor 
Field H oersted (Oe) A·m-1 10-4 
Magnetic 
moment m emu A·m
2 10-3 
Magnetization M emu/cm3 A·m-1 103 
Specific 






Sometimes, it is convenient to define the value of the magnetization per unit mass. 









where ρ is the density of the material. Throughout this dissertation, the convention of 
volume magnetization (M) is used interchangeably with specific magnetization (σ).  
When it comes to nanomaterials, there are several parameters that quantify the 
important magnetic characteristics of nanomaterials: (1) saturation magnetization; (2) 
remanent magnetization; and (3) coercivity. These magnetic components can be 
determined using a field-dependent magnetization curve (i.e., magnetic hysteresis curve), 
as shown in Figure 1.3. In ferro-/ferrimagnetic materials, M increases with H. At a 
 
 
Figure 1.3 Schematic illustration of hysteresis curve of a ferromagnetic material. 
The hysteresis curve represents the change in magnetization (M) as a function of 





sufficiently large field, M becomes independent of H. That is, M for the materials has 
reached its saturation magnetization (Ms). Next, as H decreases, M decreases. The value 
of M at H = 0 is called the remanent magnetization (Mr). The field strength required to 
reduce M to zero is called the coercivity (Hc), and is defined by the −x and +x intercepts of 
the curve. 
 
1.5 Types of Magnetism 
All substances are magnetic, but a few are magnetically much stronger than others. 
The magnetic moment of a substance results entirely from the motion of electrons in atoms. 
The nucleus also has an m, but it is insignificant with respect to the m of an electron. 
Magnetism arises from two motions of the electrons: (1) orbital motion; and (2) spin. The 
magnetic moment of spin motion is equal to that of electron motion in the first Bohr orbital, 
and, as represented in Equation 1.3, is called ‘the Bohr magneton’, µB:  
 
𝜇𝜇𝐵𝐵 = 𝑒𝑒ħ2𝑚𝑚𝑚𝑚 = 0.927 × 10−20𝑒𝑒𝑚𝑚𝑒𝑒 = 9.27 ×  10−24 𝐴𝐴 ∙ 𝑚𝑚2 (1.3) 
 
where e is charge of an electron, c is speed of light, and ħ is reduced Plank’s constant. 
Each electron in an atom has its own spin and orbital motion. The magnetic 
moments of an electron associated with spin and orbital motion are parallel to its axis of 
spin and normal to the plane of its orbital, respectively. Because these magnetic moments 
are vector quantities, a magnetic moment in an atom is the vector sum of all possible 
moments. Thus, the magnetic moments of all the electrons can cancel out, which results in 





net magnetic moment due to partial cancellation of the moments. The materials composed 
of the atoms with net magnetic moments exhibit para-, ferro-, ferri-, or antiferromagnetism. 
Magnetism in a substance can be classified into one of four categories: (1) 
diamagnetism; (2) paramagnetism; (3) antiferromagnetism; and (4) ferro/ferrigmagnetism. 
These differences arise from the interaction between atomic moments in a substance. 
Atomic moments in diamagnetic materials are zero due to the absence of unpaired electrons. 
While there are no interactions in paramagnetic materials, strong interactions between 
atomic moments are present in ferromagnetic, ferrimagnetic, and antiferromagnetic 
materials. 
Ferromagnetic materials, such as iron, nickel, or cobalt, have large magnetic 
moments, due to strong magnetic interactions between atoms.29-30 For example, the M of 
iron is ~1700 emu/cm3 at 50 Oe, while M for a typical paramagnetic material will be ~10-
3 emu/cm3 at the same field.29 In other words, ferromagnetism is at least ~100,000× 
stronger than paramagnetism. This can be attributed to the fact that, unlike paramagnetic 
substances, the interaction of the atomic moments in ferromagnetic materials is very strong 
due to the quantum mechanical effect known as direct exchange interaction. Below the 
Curie temperature, i.e., the temperature at which ferromagnets become paramagnets, all 
atomic moments in a ferromagnet become aligned (Figure 1.4A) and the strong exchange 
forces between atoms can spontaneously magnetize the ferromagnet even in the absence of 
a magnetic field. 
Similar to ferromagnetism, ferrimagnetic substances exhibit a spontaneous 
magnetization below the Curie temperature.31 Ferrimagnets are typically ionic compounds 






Figure 1.4 Schematic illustration of the atomic magnetic moments in (A) 
ferromagnetic and (B) ferrimagnetic substances. Atomic moments in a 
ferromagnetic are aligned in a parallel fashion. However, in a ferrimagnet, two 
atomic moments in the different sublattices are aligned in an antiparallel manner. 
Due to the uneven atomic moments, ferrimagnets can be spontaneously magnetized 
and show a net strong magnetization. This illustration was modified based on 
reference 29. 
 
ferrites. There are two types of magnetic ferrites with different crystal structures: (1) 
hexagonal; and (2) cubic. Barium and strontium ferrites (BaO‧6Fe2O3 and SrO‧6Fe2O3) are 
examples of ferrites with a hexagonal crystal structure. The general formula for cubic 
ferrites is MFe2O4, where M is a divalent metal ion like Mn, Ni, Fe, or Co. As mentioned, 
ferrites are ionic compounds and their magnetic properties depend on the exchange 
interactions between magnetic ions in the structure, as illustrated in Figure 1.4B.  
Figure 1.5 shows the crystal structure of cubic ferrites composed of closed packed 
oxygen ions and two sublattice sites, tetrahedral (A) and octahedral (B), that can be 
occupied by metal ions.32 The exchange interactions (i.e., superexchange interactions) of 
the magnetic metal ions are mediated by oxygen ions. Note that the oxygen ion (O2−) in 






Figure 1.5 Spinel crystal structure of a cubic ferrite with a 
general formulation (𝑀𝑀2+𝑍𝑍23+𝑂𝑂42−). (A) Two sublattices of the 
spinel structure (i.e., tetrahedral and octahedral sites), 
occupied with metal ions. (B) The cubic crystal system with 
oxygen anions (O2-) in a cubic close-packed lattice, and cations 
(M2+ and Z3+) occupying two interstices in the lattice. Note that 






A and B sites are negative, the spontaneous magnetization direction of ions in A sites is 
opposite to that of ions in B sites. This causes partial cancellation of magnetization. 
Therefore, ferrites have a net spontaneous magnetization. 
The existence of magnetic domains in a ferromagnet, another important concept in 
magnetism, was introduced by Pierre Weiss in 1906.29 A magnetic domain is defined as a 
region that has a spontaneous magnetization in one direction due to the parallel alignment 
of the individual atomic moments within the domain. It should be noted, however, that the 
magnetizations of different domains can be randomly with respect to each other, resulting 
in a net magnetization of zero. 
Magnetic domain structures are closely related to the magnetic behavior of 
ferromagnetic materials (e.g., iron, nickel, cobalt, and alloys), and ferrimagnetic materials 
(e.g., ferrites). Multiple domains can exist in a ferromagnetic material and the domains are 
separated by domain walls (a.k.a., the Bloch wall).33 Domain walls are the interfacial 
region between two domains and the magnetization direction in one domain coherently 
rotates to the direction in a neighboring domain in the boundary. The reason why a 
ferromagnet divides into various domains, rather than having the magnetization in one 
direction throughout the material, is to minimize its internal energy (i.e., magnetostatic 
energy). The size of domain is governed by the balance of several energies within the 
material, including the exchange energy, crystal anisotropic energy, demagnetizing energy, 
and domain wall energy.29, 34 
Frenkel and Doefman predicted that a particle of ferromagnetic materials below the 
linear dimensions of 10-5 cm  would have a single magnetic domain and, therefore, must 





energy is required to create domain walls than the total magnetostatic energy of a single-
domain particle. Therefore, there is a critical size (Ds) for which the single-domain state is 
favored and the magnetization direction of a single-domain particle is invariant throughout 
the magnet. 
 
1.6 Magnetism in Nanoscale 
In bulk magnetic materials, the magnetic properties depend on composition, 
crystallographic structure, magnetic anisotropic energy, structural defects, and a number 
of other factors.29, 36 However, when the size scale of the particle approaches the nanoscale, 
other parameters such as size and shape can have a strong impact on magnetic properties. 
When the measured value of a physical property is dependent on the size of the material, 
the property is said to exhibit a ‘size effect’. Among magnetic properties, Hc has a 
pronounced size effect (Figure 1.6). As the particle size decreases in a multi-domain  
 
 
Figure 1.6 Schematic illustration of variation of coercivity (Hc) as a function 
of particle diameter. Dp is a critical diameter of MNPs, at which the 
transition of superparamagnetism to ferro-/ferrimagnetism occurs. This 





region, Hc typically increases and reaches a maximum. At this point, the transition from a 
multi-domain to single-domain state occurs. Upon further reduction in particle size below 
Ds, Hc decreases to zero. 
If we consider a single-domain particle with a volume (V) and uniaxial anisotropy 
(i.e., only one easy axis), the energy of the magnetic particle is then the sum of anisotropy 
energy (Ea) and the Zeeman energy (EH), and can be written as follows, 
                                         𝐸𝐸 = 𝐸𝐸𝑎𝑎 + 𝐸𝐸𝐻𝐻 = 𝐾𝐾𝑉𝑉 sin2 𝜃𝜃 − 𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚 (1.4) 
 
where K is the anisotropy constant, θ is the angle between the direction of m and the easy 
axis, and δ is the angle between m and H (Figure 1.7A). As the size of MNPs decreases 
below a certain critical size (Dp), all of the atomic magnetic spins become aligned in the 
same direction and behave like a single magnetic moment. In this regime, single-domain 




Figure 1.7 Magnetic anisotropy of a MNP. (A) Single-domain particle with uniaxial 
anisotropy, and (B) Dependence of energy of a particle with an uniaxial anisotropy on 
the angle between the magnetic moment and the easy axis in the absence of H. This 





easy axis). The two opposite orientations with 180° along the easy axis are separated by 
the anisotropic energy barrier shown in Figure 1.7B. When a particle is small enough, the 
energy barrier (∆𝐸𝐸) of the particle decreases and, therefore, the thermal energy of the 
particle is sufficient to rapidly change the magnetization direction of the particle. Such a 
fluctuation leads to a net magnetization of zero at room temperature. This behavior is called 
superparamagnetism.29, 37 Due to the special characteristics of superparamagnetic 
nanoparticles (i.e., Mr and Hc are zero while having a high magnetic moment compared to 
paramagnetic materials), superparamagnetic nanoparticles have been extensively used in 
nanomedicine, magnetic resonance imaging contrast agents, biosensors, and bioseparations. 
 
1.7 Giant Magnetoresistance (GMR) 
Magnetoresistance (MR) is the change in resistance of metallic materials due to the 
presence or absence of an external magnetic field (Happ). This arises from the fact that the 
trajectory of an electron moving such a material can be altered by Happ. All metals exhibit 
a certain degree of MR, typically with a change in resistivity of less than 1%. However, 
Baibich et al. reported in 1988 that a structure comprised of alternating nanometrically thin 
layers of magnetic (e.g., iron) and non-magnetic (e.g., chromium) materials can undergo a 
change in MR up to 80%.38 This large change in MR is referred to as giant 
magnetoresistance (GMR). Two requirements must be met for GMR to occur: (1) the 
relative orientation of the magnetization in adjacent magnetic metal layers can change; and 
(2) the thickness of the multilayer must be less than the mean free path of an electron.39 
The GMR effect occurs due to spin-dependent scattering and transmission of conduction 





Figure 1.8.39 The magnitude of change in the resistance is a function of the thickness of 
each layer.38, 40 Figure 1.8A shows a schematic visualization of the transport of conduction 
electrons in the GMR multilayer (thicker ferromagnetic iron layers with thinner non-
magnetic chromium spacers). In the absence of Happ, antiferromagnetic coupling between 
adjacent magnetic layers holds through the entire multilayer, which results in a high 
resistance due to high scattering potentials and the suppression of short circuit effect.38  
 
 
Figure 1.8 Giant-magnetoresistance. (A) Schematic visualization of spin-dependent 
transport of conduction electrons in the multilayers of ferromagnetic and non-
magnetic materials. (B) Magnetoresistance change as a function of Happ in a 
multilayer. (C) Schematic illustration of magnetic layers separated by a non-





Under Happ, the magnetization in the ferromagnetic layers aligns in a parallel fashion, 
which leads to reduction in interface scattering and increase in transmission of the spin-
down electrons. Therefore, the resistivity in the multilayer decreases in the presence of 
Happ. 
 
1.8 Magnetoresistive Sensors 
The discovery of GMR has fueled breakthroughs not only in the magnetic data 
storage industry (e.g., GMR sensors as read heads for data retrieval from the hard-disk 
drives), but also in bioanalytical sensors. There are several types of magnetoresistive-based 
sensors developed so far, including those based on spin valve, magnetic tunneling junction, 
Hall effect, anisotropic magnetoresistance (AMR), and GMR multilayers.41 In all cases, 
MR output (i.e., read an electrical voltage change) arises from changes in the local 
magnetic field in close proximity to the sensing area. 
For bioanalytical applications, GMR sensors are commonly used as a readout tool 
in association with a sandwich immunoassay format, in which molecular targets are 
captured using specific interaction of molecular recognition elements on the sensor surface 
and then tagged with magnetic labels as described in Figure 1.9. The early work with 
GMRs used micron-sized magnetic labels and demonstrated the ability to detect the 
individual labels.42-43 In the following years, the use of MNPs as labels overcame 
limitations of the micron-sized labels (e.g., ballistic deposition of labels and screening the 
neighboring binding sites) and permitted very sensitive detection of proteins in GMR array 
sensors.17, 44-45 In addition, GMR sensor arrays have been used for real-time monitoring of 






Figure 1.9 MR sensor platform. (A) Schematic illustration of magnetic labels 
composed of magnetic core, surface coating, and affinity ligand. (B) Simplified 
scheme for magnetically labeled biomolecule detection in MR sensor. The 
magnetic field from the magnetic moment of the label bound on the sensor surface 
changes the resistance of the sensor, which results in a voltage change (ΔV) at a 
constant current. 
 
sensor modified with various antibodies.46-48 The GMR arrays were further advanced for 
the field-deployable setting by placing two chips side-by-side: a GMR sensor array and  a 
complementary metal oxide semiconductor (CMOS) chip for signal processing.49  
 
1.9 Pancreatic Adenocarcinoma 
Pancreatic Adenocarcinoma (i.e., pancreatic cancer) is the most common type of 
cancer of the pancreas. Although pancreatic cancer is the tenth most prevalent cancer in 
the United States, it is the fourth leading cause of cancer death in men and women at 5-
year survival rate of ~8%.50-51 As opposed to the steady increase in survival rates for many 
of cancers, there has been little improvement with pancreatic cancer.50-51 It is estimated 
that pancreatic cancer will become the second leading cause of cancer death in the United 
States by 2020.52 The high mortality rate of pancreatic cancer stems mainly from: (1) its 
asymptomatic presentation in early stages of progression; (2) its common symptoms (e.g., 





high sensitivity and specificity. As a result, pancreatic cancer is usually diagnosed too late 
in its progression for effective treatment (e.g., surgical removal).53 In addition, pancreatic 
cancer spreads widely to distant sites in its early stages and is resistant to most of the 
treatments available to date.54 Current diagnostic work-up for pancreatic cancer includes 
computerized axial tomography (i.e., CT scan), endoscopic retrograde 
cholangiopancreatography with stent placement, pancreas and liver biopsy, and diagnostic 
laparotomy.54 Unfortunately, there is no simple in-vitro diagnostic tool available for the 
diagnosis of pancreatic cancer.  
Firpo et al. have proposed in a series of comprehensive literature studies that a 
potential marker panel for pancreatic cancer includes 162 proteins and a diagnostic test 
screening a panel of 7 possible pancreatic cancer markers may reach an accuracy greater 
than 99% for diagnosis of pancreatic cancer.55 It has also been reported that screening 
pancreatic cancer markers in a panel improved diagnostic accuracy over a single marker 
detection.56-57 Therefore, a multiplexing diagnostic tool that can routinely screen a panel of 
biomarkers is needed. Among the many potential pancreatic cancer biomarkers, the 
strongest includes: osteopontin (OPN) 58; tissue inhibitor of metalloproteinase 1 (TIMP-1) 
59; carcinoembryonic antigen (CEA)60; carbohydrate antigen 19-9 (CA 19-9)61; 
carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM-1)62; and matrix 
metalloproteinase-7 (MMP-7).63 These biomarkers are over-expressed in the onset and 
prognosis of pancreatic cancer,53, 64 and represent an intriguing set of starting points in  the 







1.10 Dissertation summary 
 The following chapters of this dissertation are expansions of the materials discussed 
above. The main emphases of this dissertation are the synthesis, characterization, and 
biomolecule conjugation of magnetic labels, and their application in immunoassays for the 
detection of potential pancreatic cancer markers. Chapter 2 presents a method to 
encapsulate individual ferrimagnetic zinc ferrite nanocubes using a silica layer. The silica 
coating of individual magnetic nanocubes is only realized when multiple polyelectrolyte 
layers are deposited on the nanocubes prior to silica encapsulation in order to reduce strong 
magnetic interparticle couplings. Chapter 3 discusses the synthesis and magnetic 
characterization of colloidally assembled zinc ferrite magnetic beads. Since the magnetic 
properties of magnetic particles are dependent on magnetic interactions as well as other 
physical properties, this chapter aims to elucidate the difference in magnetic properties 
between seed particles and colloidally assembled magnetic beads.  Chapter 4 focuses 
mainly on applying the colloidally assembled zinc ferrite magnetic beads to GMR-based 
immunoassays. The detailed procedures to fabricate magnetic labels are discussed and the 
performance of in-house magnetic labels is compared to the commercially available 
magnetic beads. Chapter 5 furthers the work in Chapter 4 through the development and 
optimization of multiplexed GMR-based immunoassays for the detection of potential 
pancreatic cancer markers. Furthermore, the efforts to develop multiplex immunoassays in 
serum, using our GMR sensor and our magnetic labels, are elaborated. In summary, this 
dissertation describes the efforts for the development of an in-vitro diagnostic tool for the 
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FERRITE NANOCUBES ENABLED BY LAYER-BY- 
LAYER POLYELECTROLYTE DEPOSITION 
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Encapsulation of Ferrimagnetic Zinc Ferrite Nanocubes Enabled by Layer-by-layer 
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2.1 Introduction 
 The synthesis and preparation of magnetic nanoparticles (MNPs) with large 
magnetic dipole moments, m, have been gaining traction in a variety of technologies, 
including those focused on magnetic recording media,1 biological2 and environmental 
separations,3 chemical catalysis,4 nanomedicine,5 ferrofluid applications,6 magnetic 
resonance imaging (MRI) contrast reagents,7 and biosensors.8, 9 However, one of the 
shortcomings of high m MNPs is their tendency to spontaneously aggregate. Approaches 
to prevent MNP aggregation include creating a shell around the MNPs,10 fabricating 





superparamagnetic behavior is observed.12 Superparamagnetism (at 298 K) occurs in 
single-domain ferro- and ferrimagnetic nanoparticles of sufficiently small size that their  
magnetic dipole undergoes random thermal fluctuations in the absence of an external 
magnetic field (H); this situation results in the absence of an observable moment.13 Despite 
the advantage of zero residual magnetism afforded by superparamagnetic nanoparticles 
(SPMNPs), the diminution in MNP size results in a commensurate decrease in m, which 
can limit utility. For example, the signal-to-noise ratio of a magnetic biosensor is 
proportional to m, and MNPs with large m are generally required in magnetic drug delivery 
and cell separation. SPMNPs are also not suitable for permanent magnetic storage media, 
which require ferro- or ferrimagnetic nanoparticles (FMNPs) with nonzero coercivity (HC) 
and remanent magnetization (MR). 
In addition to tailoring MNP size to counteract magnetic interparticle attraction, 
several particle-coating strategies have been used with similar results. Simple surface-
ligand exchange has been used to effectively stabilize SPMNP dispersions.14-16 However, 
ligand-exchange does not mitigate the aggregation of FMNPs. In these cases, polymeric 
coatings have been employed to avoid magnetically induced aggregation during and after 
synthesis. The charged or polar groups of the polymer stabilize moderate m MNPs via 
electrostatic repulsion and the physical coating limits particle-particle approach distance.17-
19 In instances of large m FMNPs, extraordinarily strong electrostatic repulsion or an 
increase in the MNP-MNP closest-approach induced by thicker polymeric coatings is 
necessary to produce a stable FMNP colloid.17-19 The effectiveness of these polymeric 
coatings, however, is generally limited to FMNPs smaller than 50 nm in size. 





in a shell of gold, graphite, or silica creating a core-shell architecture (core@shell).15 This 
form of encapsulation has several advantages over other coating strategies: 1) it can 
increase the MNP-MNP closest approach distance thereby reducing interparticle 
interactions; 2) it protects the magnetic core from dissolution; and 3) it can be modified 
with molecular recognition elements (e.g., antibodies, nucleic acids) by established linking 
chemistries. Among those coating materials, silica is biocompatible and can further 
enhance colloidal stability in aqueous media since the terminal hydroxyl groups are ionized 
at the pH of physiologically relevant matrices.20 Although the application of silica coatings 
on small FMNPs has been reported,1 there are few reports detailing the encapsulation of 
large FMNPs with high m. In these scenarios, silica encapsulation often leads to aggregates 
of particles embedded in a silica matrix.21-23 However, Kolhatkar et al. have reported that 
FeCo ferromagnetic nanocubes (>150 nm in size) with a high saturation magnetization, Ms, 
could be coated with silica after stabilizing with a layer of polyvinylpyrrolidone (PVP),10 
and Marcelo et al. described the stabilization of hydrophobic Fe3O4 ferrimagnetic 
nanocubes (>70 nm in size) in water by coating the particles with silica under sonication 
after citric acid ligand-exchange.24 While it appears that these intermediary coating 
procedures were sufficient to stabilize the particles prior to silica encapsulation, it is not 
clear that a high yield of single-core, silica-coated MNPs was realized. In our experience, 
these methods are not effective in stabilizing >100 nm zinc ferrite nanocubes with Ms ~100 
emu/g. 
Herein, we report a novel method for the production of discrete, silica-coated 
ferrimagnetic zinc ferrite nanocubes (ZFNCs). High-moment (m~10-13 emu/particle at H 





ether and oleic acid. The resulting hydrophobic oleic acid surface-molecules of as-
synthesized ZFNCs were replaced with a hydrophilic ligand and transferred to aqueous 
media. To further increase the suspension stability of the seed ZFNCs, a total of six layers 
of two alternating polyelectrolytes, polyallylamine (PAAm) and polystyrene sulfonate 
(PSS), were deposited by a layer-by-layer (LbL) process. The LbL-stabilized ZFNCs were 
then encapsulated with silica, resulting in primarily discrete silica-coated ZFNC 
(ZFNC@SiO2) particles. The ZFNC@SiO2 particles were characterized by electron 
microscopy, energy dispersive X-ray spectroscopy, powder X-ray diffraction, dynamic 
light scattering, infrared spectroscopy, and vibrating sample magnetometry. 
 
2.2 Experimental Section 
2.2.1 Materials 
Iron acetylacetonate (Fe(acac)3, 99%), zinc acetyl-acetonate (Zn(acac)2, 95%), 
benzyl ether (99%), tetraethyl orthosilicate (TEOS, 95%), dimercaptosuccinic acid (DMSA, 
99%) and poly(sodium-p-styrene sulfonate) (PSS, linear, Mw ~70,000 g/mol) were 
purchased from Acros organics (USA). Polyethyleneimine (PEI, branched, Mw ~25,000 
g/mol) and citric acid (CA, 99%) were received from Sigma-Aldrich (USA). 
Polyallylamine hydrochloride (PAAm, linear, 120,000<Mw<200,000 g/mol), oleic acid 
(90%) and ammonium hydroxide (NH4OH, 30%) were purchased from Alfa Aesar (USA). 
Ethanol (EtOH, 200 proof) was acquired from Decon Lab (USA). Dimethyl sulfoxide 
(DMSO, 99%) and toluene (99%) were obtained from Fisher Scientific (USA). All 






2.2.2 Synthesis of Magnetic Nanoparticles 
The synthesis of cubic ferrimagnetic nanoparticles was adapted from the procedure 
of Noh et al.25 Typically, 0.353 g Fe(acac)3 and 0.395 g Zn(acac)2 were added to a mixture 
of 1.2 mL oleic acid and 10.0 mL benzyl ether. This solution was heated under nitrogen at 
a rate of 15 ˚C/min to 290 ˚C and then refluxed for 30 min. After cooling to room 
temperature, 20 mL of EtOH was added to precipitate cubic zinc ferrite particles. The 
sample was then centrifuged at 10,190×g for 10 min and the supernatant was discarded. 
This washing procedure was repeated two more times. The MNPs were finally resuspended 
in 10 mL of toluene. 
 
2.2.3 Ligand-exchange of Magnetic Nanoparticles 
Surface functionalization with a hydrophilic exchange ligand (i.e., CA, DMSA, and 
PEI) was used to transform the as-prepared hydrophobic ZFNCs to a hydrophilic state for 
subsequent suspension in water. A 10 mL aliquot of ligand solution (ligand concentration 
~70 mg/mL in DMSO) was added to the MNP suspension, followed by a 3-h sonication at 
60 ˚C and agitation on a rocking table for 16 h. The hydrophilic, ligand-coated MNPs were 
next washed three times with 10 mL EtOH and resuspended in 18.2 MΩ-cm deionized 
water (DI H2O). The final concentration of the ligand-exchanged MNPs was ~5 mg/mL. 
 
2.2.4 Layer-by-layer (LbL) Deposition of Polyelectrolytes 
Prior to LbL deposition, 1.0 mL of the PEI-coated zinc ferrite particles (~5 mg) was 
diluted to 10 mL with DI H2O. This step was followed by the addition of 5.0 mL aqueous 





10 min) and the supernatant was removed. The MNPs were then resuspended in 10 mL DI 
H2O and a 200 μL aliquot was removed for characterization. This process was repeated 
two more times. A subsequent layer of PAAm was formed using the same procedure with 
an aqueous solution of PAAm (10 mg/mL). These two deposition steps were repeated until 
the desired number of polyelectrolyte layers were deposited; typically six polyelectrolyte 
layers were deposited prior to silica coating. The terminal PAAm layer possessed a net 
positive surface charge (−NH3+) in DI H2O (pH = 6.5). The resulting MNPs were 
resuspended in DI H2O to a final concentration of ~5 mg/mL. 
 
2.2.5 Silica Coating 
Silica was deposited on the polyelectrolyte-coated zinc ferrite seed particles by a 
modified Stöber method.26 Briefly, 1.0 mL of the LbL-coated MNP suspension (~5 mg in 
DI H2O) was added to 10 mL EtOH, followed by the sequential addition of 0.65 mL DI 
H2O and 1.0 mL TEOS solution (25 μL/mL in EtOH) at room temperature. The magnetic 
suspension was sonicated for 90 min after which 0.98 mL NH4OH was added drop-wise to 
the suspension with continued sonication. Then, another 1.0 mL of TEOS solution was 
added drop-wise, which was followed by a 90-min sonication, and then agitation on a 
rocker plate for 18 h. The silica-coated MNPs were isolated after three centrifugation 
(10,190×g, 10 min) steps in EtOH and a final resuspension in 10 mL DI H2O. The overall 









































2.2.6 Electron Microscopy 
Field-emission scanning electron microscopy (FESEM) was performed with a 
Hitachi S-4800 equipped with an energy dispersive X-ray (EDX, INCA, Oxford 
Instruments) spectroscopy module. In general, MNP samples for imaging and EDX 
analysis were prepared by pipetting 20 μL aqueous particle suspension onto a 1×1 cm2 
silicon chip that was allowed to dry at ambient temperature. Images were obtained at an 
acceleration voltage of 15 kV. 
For transmission electron microscopy (TEM), a JEM-2800 S/TEM instrument 
(JEOL, Japan) was used at 200 kV with the magnetic samples dropcast on a 3-mm carbon-
coated copper grid. EDX mapping data was collected with a 1 nm probe at a 512×512 pixel 
density, ~0.5 nm/pixel. 
 
2.2.7 X-ray Diffraction (XRD) Analysis 
The crystallinity of the MNPs was determined by powder X-ray diffraction (XRD, 
Rigaku, D/max-2200V, Japan). XRD was carried out with Cu Kα radiation (λ = 0.154059 
nm) and operated at 40 kV and 30 mA. The diffractograms were obtained with a 2θ step of 
0.02˚ at 0.5 s/step from 15˚-100˚. Three sample libraries, the International Centre for 
Diffraction Data (ICDD), the RUFF Project Database,27 and the National Bureau of 









2.2.8 Infrared (IR) Spectroscopy 
IR transmission spectra were collected using a Nicolet Magna 850 Fourier 
transform IR spectrometer equipped with a liquid nitrogen-cooled mercury cadmium 
telluride detector. Spectra were collected in a nitrogen atmosphere using 512 scans at a 
resolution of 0.198 cm-1 with p-polarized light. The MNP samples were prepared as 1% 
particle (w/w) dispersions in KBr. 
 
2.2.9 Dynamic Light Scattering (DLS) 
The zeta (ζ)-potential and hydrodynamic sizes of particle samples were measured 
using a Zetasizer Nano (Malvern Instruments, U.K.) with a disposable folded capillary cell. 
The particles were diluted to 0.1 wt % in DI H2O. Nanoparticle suspensions were sonicated 
for 2 min before being injected into the cell and left to equilibrate for 2 min prior to 
measurement. The specific conditions for DLS measurement are described in the 
Supporting Information. 
 
2.2.10 Vibrating Sample Magnetometry (VSM) 
Magnetic hysteresis curves, isothermal remanent magnetization (IRM), and dc 
demagnetization (DCD) remanence measurements were carried out using a vibrating 
sample magnetometer (VSM EZ7, MicroSense, Lowell, MA) operated at 298 K. For the 
measurements, MNPs were mounted on a piece of Kapton tape which was folded in half 
and gently compressed in a pellet press to fix the particles to the tape and remove trapped 
air. Another piece of the tape without the MNPs served as the blank. The signal of the blank 





measurements are provided in the Supporting Information. 
Throughout this work, we have adopted the convention of using the term 
magnetization, M, interchangeably with mass magnetic moment, σ. However, by definition, 
M has units of emu/cm3 and σ has units of emu/g. 
 
2.3 Results and Discussion 
Monodispersed ZFNC seed particles were synthesized by thermal decomposition 
of zinc and iron acetylacetonates.25 Shown in Figure 2.2A is a representative SEM image 
of the as-synthesized ZFNCs and their size distribution. These cube-shaped particles have 
an average edge length of ~130 nm and their faces appear rough, which is usually found 
with particles larger than 100 nm and is most likely due to crystalline defects and step 
edges. The as-synthesized particles are composed of Fe, O, and Zn and have an empirical 
formula of [Zn0.41Fe0.59]Fe2O4 determined by EDX (Figure A.1). The X-ray powder 
diffractogram for the ZFNCs (Figure A.2) shows that the particles are crystalline with 
characteristic diffraction peaks of magnetite (Fe3O4, ICDD No. 01-086-0510 and RRUFF 
Database No. R080025) and zinc ferrite (ZnFe2O4, NBS Monograph29 and RRUFF 
Database No. R070137). 
The ZFNCs then underwent a ligand-exchange process to replace the hydrophobic 
surface group, oleic acid,30 with a hydrophilic species. We chose to study CA, DMSA, and 
branched PEI based on their previously demonstrated effectiveness as ligand-exchange 
agents.31 The ζ-potential values, which are an indication of surface charge and, therefore, 
colloidal stability, measured for the CA-, DMSA-, and PEI-coated ZFNCs were –6.5 ± 3.6, 






Figure 2.2 (A) Representative scanning electron 
micrograph of as-synthesized ZFNCs. (B) Histogram of 
the edge length of as-synthesized ZFNCs. 
 
two systems are consistent with the deprotonation of the carboxylic acid groups of CA and 
DMSA, whereas the positive value for the third system follows the expectation for 
protonation of the PEI amine groups. Of the three ligand-exchanged ZFNCs, only the PEI-
coated ZFNCs appear to have an absolute ζ-potential indicative of 
stable colloids (∣ζ∣ > 30 mV). Indeed, when the CA- and DMSA-coated ZFNCs were 
suspended in DI H2O, they precipitated within 10 min. The PEI-coated ZFNCs, however, 
remained suspended in DI H2O for a few hours. The colloidal stability due to PEI, 
compared to CA and DMSA, is believed to arise from: 1) the multivalent adsorption of the 





mono- or divalent ligands,32, 33 and 2) an increase in MNP-MNP separation due to PEI-
induced steric hindrance and electrostatic repulsion of the profuse protonated amine groups. 
We note that the ligand-exchange procedures appeared to have no effect on the 
morphology of seed ZNFCs, which was investigated by SEM.  
Once the ZFNCs were stabilized with PEI and effectively dispersed in aqueous 
media, silica encapsulation was attempted to create a potentially more suitable species for 
bioanalytical applications. Coating nanoparticles that possess a nonzero remanent 
magnetization with silica or metals can be problematic due to their tendency to aggregate, 
which is brought on by strong interparticle magnetic dipole-dipole interactions; indeed, 
there are only a few reports detailing the successful encapsulation of these particles.10, 24, 
33 Shown in Figure 2.3 are SEM micrographs of the CA-, DMSA-, and PEI-modified 
ZFNCs after silica coating. While a one-step ligand-exchange successfully altered the 
surface properties of our ZFNCs (i.e., from hydrophobic to hydrophilic), the particles 
tended to aggregate into linear chains during silica encapsulation. Individual ZFNC@SiO2 
particles were not observed; rather, linear aggregates of ZFNCs embedded in a silica 
matrix were formed. It is important to note that the high ζ-potential of the PEI-coated 
ZFNCs, indicating strong electrostatic repulsion between PEI-modified ZFNCs, did not 
prevent the seed ZFNCs from aggregating during the silica coating procedure. 
Linear or face-to-face assemblies of different MNPs are frequently observed in 
dispersions or silica matrices.34-36 The mechanism of MNP aggregation can involve several 
phenomena including Brownian motion (thermal energy), magnetostatic and electrostatic 
forces, and van der Waals interactions.37 We believe that the linear arrangement of ZFNCs 







Figure 2.3 Scanning electron micrographs of the linear 
arrangement of ZFNCs in silica matrices. The as-
synthesized ZFNCs were ligand-exchanged with (A) 






magnetic dipole-dipole interaction between the nanocubes leading to the observed 
anisotropic structures (e.g., linear chains, flux-closure rings, etc.) is stronger than Brownian 
forces, van der Waals interactions, or electrostatic forces that are typically responsible for 
isotropic aggregation.38 
 To prevent linear chain formation of the ZFNC seeds, a series of polyelectrolyte 
layers were applied to the seed ZFNCs using an LbL technique. The LbL deposition of 
polyelectrolytes is a versatile method used to create robust, polymeric multilayer 
structures.39-42 In principle, fabrication of polyelectrolyte multilayers utilizes electrostatic 
interactions between oppositely charged polyelectrolytes, which enables cyclic deposition 
of oppositely charged polyelectrolytes. As a consequence, LbL deposition enables one not 
only to control the thickness of multilayers in nanometer scale, but also to take advantage 
of the polyelectrolyte charge. Of the potential polyelectrolytes, we opted to assess the 
utility of PSS and PAAm, which contain sulfonate and amine groups, respectively. As the 
PEI-coated seed ZFNCs were positively charged, PSS was deposited as the first 
polyelectrolyte, followed by the deposition of PAAm. We repeated this cycle until six 
polyelectrolyte layers were deposited. The deposition of each polyelectrolyte layer was 
characterized by ζ-potential and IR (Figure 2.4). The charge reversal between PSS layers 
(odd numbered) and PAAm terminal layers (even numbered) in Figure 2.4A indicates that 
the sequential deposition of polyelectrolytes was successful. The IR spectra shown in 
Figure 2.4B follow the stepwise formation of ZNFC@SiO2, starting with the PEI-coated 
ZFNCs (black line). 
All three spectra have strong bands around 580 cm-1, which are associated with Fe-






Figure 2.4 (A) ζ-potential measurements showing surface charge reversal of the 
ZFNC seeds in the course of LbL deposition of PSS (odd layer number) and 
PAAm (even layer number). (B) IR spectra of the particles after PEI ligand-
exchange, LbL deposition of PSS and PAAm, and silica encapsulation. Note 
that the particle sample of ZFNC@LbL used in the IR study had six 
polyelectrolyte layers. 
 
sample are due to the NH and NH2 deformation in PEI, and the broad band from 3200 to 
3425 cm-1 is assigned to the N-H stretching vibration.44 These spectral features confirm the 
presence of PEI after ligand-exchange. After depositing the six polyelectrolyte layers 
(red line), sharp bands at 1007 and 1037 cm-1 are observed and attributed to the S=O sy
mmetrical stretching vibration and an aromatic in-plane vibration of PSS, respectively.45 
There is also a band around 1630 cm-1, which is a bending mode of the primary amine in 





of PSS and PAAm polyelectrolyte layers on the ZFNC@PEI particles. 
Discrete ZFNC@SiO2 particles were subsequently formed using a modified Stöber 
procedure. The thickness of the silica layer was ~30 nm and the particles retained their 
cubic morphology (Figure 2.5). The discrete nature of the ZFNC@SiO2 particles is 
observed by noting the distance between particles is twice the thickness of the silica shell. 
The IR spectrum of the silica-coated ZFNCs (green line in Figure 2.4B) shows a broad, 
strong band at 1100 cm-1, which arises from the asymmetric vibration of Si-O bonds.  
Strong asymmetric and symmetric vibrations of Si-OH and Si-O are observed at 950 and 
795 cm-1, respectively.47 A broad band at 3500 cm-1 and a slightly weaker band around 
1600 cm-1 are attributed to O-H stretching and bending vibrations, respectively; these two 
bands are likely from surface hydroxyl (–OH) groups of silica and adsorbed water.48 The 
measured ζ-potential of ZFNC@SiO2 particles in DI H2O was –63.1 ± 7.0 mV, indicating 
that the surface (–OH) groups are deprotonated, which is consistent with pI of silica (~pH  
 
 
Figure 2.5 Electron micrograph of the ZFNC@SiO2 particles assisted via LbL 
deposition. The discrete nature of the ZFNC@SiO2 particles is shown in the 






2).20 It should be noted that the XRD peaks of the silica-coated ZNFCs closely resemble   
the Bragg reflections of the seed ZFNCs (Figure A.2), indicating that the silica shell is 
amorphous and the crystallinity of the magnetic core is not affected by encapsulation. 
The particle size progression of the PEI-, polyelectrolyte-, and silica-coated ZFNCs 
was also followed by DLS (Figure A.3) and compared to the SEM micrograph analysis 
(Table A.1). The average size of particle increases with synthesis step. The hydrodynamic 
size based on intensity distribution (Dh,int) of the PEI-coated ZFNCs was ~225 nm prior to 
LbL deposition. After the sequential deposition of six polyelectrolyte layers and silica 
coating, Dh,int increased to 297 nm and 360 nm, respectively. Considering a sphere is the 
only object whose size can be correctly described by a single dimension in DLS, the Dh,int 
of a cube is roughly interpreted as the maximum corner-to-corner dimension of that cube 
(√3 longer than a cube edge).49 Therefore, the hydrodynamic size intensity distributions 
of the ZFNC@SiO2 from the DLS measurements are consistent with those determined 
from SEM (Table A.1). 
EDX mapping analysis acquired during the course of TEM imaging provided 
chemical composition and elemental distribution information of discrete ZFNC@SiO2 
particles. Representative results are presented in Figure 2.6. The images indicate that Fe, 
Zn, and O are distributed throughout the particle core and the distribution of Si and S is 
weighted towards the encapsulating shell. It is important to note that polyelectrolyte layers 
deposited prior to silica encapsulation persist after silica coating. The S signal is presumed 
to be due to the presence of PSS between the core and the SiO2 shell, which is clearly 
observed in Figure 2.6A — the composite of grayscale, Fe, Si, and S. The ability to capture 







Figure 2.6 EDX images depicting elemental distribution of (C) 
Fe, (D) Zn, (E) Si, (F) S, and (G) O. The figure shown in (A) 
is a composite of the grayscale TEM image (B) and Fe, Si, and 





nanoparticles, fluorophores, or other materials could potentially be incorporated within the 
polyelectrolyte layers, creating multifunctional silica-coated ferrimagnetic 
nanoparticles. For example, by incorporating quantum dots within the multilaye r 
polyelectrolyte structure, further development of multi-modal imaging and theranostic 
agents could be realized.50 
To delineate the effect that the number of polyelectrolyte layers has on the 
formation of ZFNC@SiO2 particles, we attempted to silica coat the seed particles with 
different numbers of polyelectrolyte layers. The number of polyelectrolyte layers is a 
critical parameter to keep the ferrimagnetic ZFNCs separated during the silica coating 
process. Shown in Figure 2.7A-D are silica-coated ZFNCs with zero, two, four, and six 
polyelectrolyte layers respectively. In general, as the number of polyelectrolyte coatings 
increases, the tendency to form linear chains or aggregates during silica encapsulation 
decreases. Very few single-core, ZFNC@SiO2 particles were obtained when the seed 
ZFNCs were coated with only 0 or 2 polyelectrolyte layers. The seed ZFNCs with four 
polyelectrolyte layers demonstrated few single-core ZFNC@SiO2 particles, and large 
aggregates still dominate. Once the ZFNCs are encapsulated with six or more 
polyelectrolyte layers, discrete ZFNC@SiO2 particles are clearly evident. The SEM images 
in Figure 2.7D and Figure 2.5 show the gap distance between two seed particles is roughly 
twice as large as the silica layer thickness, indicative of discrete ZFNC@SiO2. Furthermore, 
the DLS size distributions of the different ZFNC@SiO2 samples are in good agreement 
with the SEM data in Figure 2.6. Only the silica-coated ZFNCs with six polyelectrolyte 
layers showed one prominent Dh,int peak (Figure A.4). As expected, the average 






Figure 2.7 SEM images of silica-coated ZFNCs. The seed ZFNCs had different 
numbers of polyelectrolyte layers prior to silica encapsulation: (A) 0, (B) 2, (C) 4, and 
(D) 6 layers. 
 
layer; a testament to aggregation remediation. The colloidal stability of the ZFNC@SiO2 
particles also increases with the number of polyelectrolyte layers applied. The 
ZFNC@SiO2 particles with six polyelectrolyte layers remained suspended for over 12 h in 
DI H2O. However, the ZFNC@SiO2 particles with 0 and 2 polyelectrolyte layers 
sedimented in less than 30 min in DI H2O.  
Together, the DLS and SEM data indicate that at least six polyelectrolyte layers are 
essential to stabilize the seed particles and ensure successful fabrication of discrete 
ZFNCs@SiO2 particles. We believe that the success of LbL stabilization is due to an 
increase in the closest approach distance between the ZFNCs, and therefore a reduction in 
magnetic dipole-dipole interaction, and electrostatic repulsion brought on by the charge of 





To understand the ramifications that the coatings have on the resulting magnetic 
properties of the ZFNCs, a series of magnetometry experiments were performed. Shown 
in Figure 2.8 are representative magnetization curves of PEI- (black), LbL-coated 
ZFNCs(red), and ZFNC@SiO2 (green). The measured values of Mr and Hc for the PEI-
coated ZFNCs are 16.8 emu/g and 50.5 Oe, respectively, indicating that the ZFNCs are 
ferrimagnetic at room temperature. The value for Ms (this is the quotient of the measured 
sample moment to the total mass of particles in the sample) of the PEI-coated ZFNCs is 
98.4 emu/g at 298 K. This value is higher than the reported Ms of magnetite nanoparticles 
(80-85 emu/g),33, 51 which is consistent with the Ms enhancement of Zn-doped Fe3O4 
nanoparticles.52, 53 The magnetic moment of one ZFNCs (Table A.2) is estimated at 10-13 
emu/particle (H = 150 Oe) and 10-12 emu/particle at fields sufficient to saturate the sample 
(15,000 Oe). These values are also higher than that reported for Fe3O4 and other 




Figure 2.8 Hysteresis curves of the ZFNCs with different coatings; 
PEI (black), LbL (red), and silica (green). Hc increases (inset) with 






emu/g after six polyelectrolyte coatings and 46.9 emu/g after silica coating. This decrease 
is due to the increased mass of the non-magnetic coatings. Despite the decrease of Ms after 
silica coating, both the ZFNCs and ZFNC@SiO2 particles are easily collected from a 10-
mL suspension using a 1-cm3 neodymium magnet (~4,000 Gauss) in 10 s or 20 s, 
respectively. Commensurate with the decrease in Ms, Hc increases slightly from 50.5 Oe 
to 51.8 Oe to 61.6 Oe when coated with PEI, LbL polyelectrolytes, and silica, respectively. 
We believe that the increase in Hc is a result of decreased magnetic dipole coupling. The 
polyelectrolyte and silica shells physically separate the core ZFNCs, which causes a 
reduction of the interaction field (magnetic dipole interactions decay as the cube of 
interparticle separation),55 leading to an increase in Hc. Morales et al. observed a similar 
coercivity enhancement when γ-Fe2O3 MNPs were dispersed in a silica matrix.56 This 
observation is in agreement with the report by Che et al., in which they demonstrated that 
magnetization reversal is assisted by strong dipole coupling, which results in a decrease in 
Hc.57 
Particle-particle interactions can be assessed by remanence techniques (see 
Supporting Information). The quantitative validity of these approaches depends on several 
assumptions: the particles are assumed to be single-domain ferromagnetic particles with 
uniaxial anisotropy. Given the size of our ZFNPs, we anticipate the particles are comprised 
of multiple domains. However, remanence techniques, which are based on comparing the 
IRM curve to the DCD curve, can still provide qualitative interaction information in 
systems that deviate from the basic assumptions.  
Shown in Figure 2.9A are Henkel plots of three particle samples: PEI-coated 






Figure 2.9 (A) Henkel and (B) 𝛿𝛿𝛿𝛿 plots produced from IRM and DCD 
measurements. The δm minima occur at 100, 150, and 350 Oe for the 
PEI-, LbL-, and silica-coated ZFNCs respectively 
 
(open squares). All three MNPs demonstrate negative curvature from the Wohlfarth line 
(gray line in Figure 2.9A), with the magnitude of curvature decreasing from ZFNC@PEI 
to ZFNC@LbL to ZFNC@SiO2. The negative deviation from the Wohlfarth line originates 
from magnetic dipole-dipole interactions.58 As the interaction increases, the magnitude of 
deviation increases. Thus, the magnetic dipole-dipole interaction of the PEI-coated 
particles is reduced by LbL-polyelectrolyte coating and the interaction is further lessened 





A modified form of the Henkel representation, the δm plot, provides particle 
interaction information as a function of H. Shown in Figure 2.9B are δm plots of the three 
ZFNC systems. A non-interacting assembly of single-domain ferromagnetic particles with 
uniaxial anisotropy has a δm = 0 at all H. However, all three ZFNC systems demonstrate 
negative deviations from δm = 0. A field-shift of the minimum of the δm plot to larger 
values as a function of coating step is also observed. That is, δm for the PEI-coated ZFNCs 
reaches a more negative value than that of the other two samples and decays faster at lower 
fields. Since the interparticle distance between the PEI-coated ZFNCs is smaller than those 
of the multiple polyelectrolyte- and silica-coated ZFNCs, the strong dipole coupling 
interaction field of the PEI-coated ZFNCs aids the other ZFNCs in close proximity to 
reverse their magnetization at a lower applied field. Therefore, an ensemble of the PEI-
coated ZFNCs demagnetizes faster than that of ZFNCs encapsulated by further coatings. 
This clearly indicates that the silica encapsulating layer separates ZFNCs and reduces their 
dipole-dipole interaction. Similar results for ferromagnetic FePt and silica-coated 
ferrimagnetic CoFe2O4 nanoparticle systems have been reported by others.1, 18, 58, 59 The 
reduction of magnetic dipole coupling interactions by silica encapsulation is also consistent 
with the enhancement of the magnetic hardness (coercivity) of the ZFNCs@SiO2.60 
 
2.4 Conclusion 
The drive to create silica-encapsulated MNPs stems not only from the fact that the 
shell acts to reduce magnetic-induced aggregation, but also that silica provides a surface 
amenable to in vivo use and is conducive to functionalization with molecular recognition 





MNPs is challenging due to the strong interparticle attractive forces that exist during the 
coating procedure. 
We have developed a method to deposit a uniform silica coating around high 
moment (m~4×10-13 emu/particle at H = 150 Oe) ferrimagnetic zinc ferrite nanocubes 
(~130 nm). By depositing multiple polyelectrolyte layers around ZFNCs using an LbL 
process, a MNP suspension can be stabilized allowing the preparation of uniformly-coated 
individual ZFNC@SiO2 particles. The polyelectrolyte multilayers increase the particle-
particle closest approach distance and provide an increased surface charge, which in turn 
helps minimize dipole-induced aggregation. Our results indicate that successful creation of 
discrete core-shell nanocubes is realized only after depositing multiple polyelectrolyte 
layers. Without the intermediary polyelectrolyte layers, magnetic dipole-dipole 
interactions lead to the formation of linearly chained ferrimagnetic nanoparticles embedded 
in a silica matrix. 
We foresee this encapsulation method being implemented to easily and routinely 
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INFLUENCE OF NANOPARTICLE ARRANGEMENT ON 
MAGNETIC PROPERTIES: MAGNETIC 




Recent progress in nanoparticle synthesis and the ensuing control of size and 
morphology have triggered strong interest in the properties of magnetic nanoparticles. In 
bulk materials, magnetic properties are controlled by composition, crystallographic 
structure, magnetic anisotropic energy, and structural defects.1 Interestingly, when the size 
of these materials approaches the nanometer length scale, their magnetic properties can 
differ markedly from those of their larger (bulk) analogs due to the importance of size and 
shape at such small size scales. For example, bulk ferro-/ferrimagnetic materials can 
spontaneously magnetize, whereas a single-domain ferro-/ferrimagnetic nanoparticle can 
have a zero remanent magnetization (Mr) and coercivity (Hc) (i.e., superparamagnetism) 
of zero after the removal of an external magnetic field (H). Due to the large surface-to-
volume ratio of nanoscale objects, shape associated with surface atoms can affect magnetic 





with the same volume and composition have different saturation magnetization (Ms) values, 
which resulted from the fact that the spherical MNPs have a higher percentage of 
disordered magnetic spins at the surface than the cubic MNPs.3   
 Beyond the nanoscale effect of size and shape, magnetic interactions can also affect 
their magnetic properties of MNPs. Magnetic interactions can include exchange coupling 
(i.e., intraparticle interaction) and magnetic dipolar interaction (i.e., interparticle 
interaction). Magnetic exchange coupling refers to interactions of magnetic spins between 
two adjacent magnetic layers.5 Indeed, changes in magnetic properties due to the exchange 
coupling are often observed in core-shell (core@shell) nanoparticles. Magnetic exchange 
coupling between ferromagnetic and antiferromagnetic layers in core@shell nanoparticles 
can provide an extra source of anisotropy.6-8 In another example, when partially oxidized 
cobalt nanoparticles (i.e., Co@CoO) are cooled in the presence of a magnetic field, the 
hysteresis of the particles is no longer symmetrical about the origin, but is horizontally 
shifted along the applied field axis.7 This unusual property of field-cooled Co@CoO 
particles arises from exchange coupling at the interface of ferromagnetic Co and 
antiferromagnetic CoO (a.k.a., exchange bias). 
Controlling magnetic properties through interparticle dipolar interactions is of great 
interest in magnetic materials, including superlattices, nanoparticle assemblies, and 
nanocomposites.9-14 In these materials, the surface coating on the magnetic material plays 
a significant role in manipulating the nature and strength of interparticle interactions. To 
control interparticle interactions, MNPs are often dispersed in a solid matrix, such as silica 
or epoxy, with different concentrations. These coatings (e.g., organic molecules or 





exchange coupling interactions between surface atoms, but also increase the distance 
between particles, the changes of which manipulate the dipole-dipole interactions. The 
recent work by Dai et al. is an example of how particle-particle proximity can affect 
magnetization. Their work compared the magnetization of cobalt ferrite nanoparticles with 
those of the same particles after encapsulation with a silica coating. The data showed that 
the closer proximity between the uncoated particles and the resulting increase in dipole-
dipole interactions caused a decrease in Hc due to assisted magnetization reversal.15 A 
similar effect was observed for ferromagnetic FePt nanoparticles and silica-coated zinc 
ferrite nanocubes.16-17 Cobalt nanoparticles incorporated into mesoporous silica aligned in 
a chain and produced a higher Hc than either noninteracting or randomly aggregated 
particles.18 Hc of spherical γ-Fe2O3 particles decreased when dispersed in a silica matrix at 
low volume fraction, which corresponds to the predicted reduction in interparticle 
interaction.19 As described above, the magnetic properties of MNPs are not only 
determined by physical properties (i.e., size and shape), but also controlled by magnetic 
interactions (i.e., exchange coupling and dipolar interactions). Therefore, understanding 
the influence of magnetic interactions on the magnetic properties of nanomaterials is 
fundamentally important, which eventually enables fine tuning of magnetic properties of 
the materials for a specific application. 
 Development of MNP assemblies using bottom-up approaches is an emerging field 
of research because it is a facile way to develop a new material whose properties can be 
designed by changing the arrangement of individual MNPs (i.e., changing magnetic 
interactions).1, 12, 20-21 The magnetic properties of MNP assembly are not only determined 





of those particles. Peddis et al. reported that the formation of iso-oriented, spherical 
assemblies of cobalt ferrite nanoparticles induces an increase in Hc and Mr, compared to 
the random aggregates of the nanoparticles.22 Also, due to the collective magnetic behavior 
of MNP clusters/assemblies, they are more responsive to an external H than individually 
dispersed MNPs, which can potentially serve as contrast agents in in-vivo imaging and 
carriers for drug-delivery.23-24  
The focus of this chapter is the investigation of the effect of arrangement of MNPs 
on their magnetic properties by comparing zinc ferrite nanoparticles (ZFNPs) and 
colloidally assembled magnetic beads (ZFMBs). To this end, ZFNPs (~11 nm) were 
synthesized using thermal decomposition. The ZFMBs (~170 nm) were created by 
assembling ZFNPs into a larger bead using an emulsion-based bottom-up assembly. First, 
the physical properties of ZFNPs and ZFMBs were carefully characterized for size, shape, 
and crystallinity using electron micrograph and X-ray diffractometry. Possible crystal 
structure deformation or oxidation of ZFNPs, which may occur in the assembling 
procedure, was investigated using Raman spectroscopy and high-resolution electron 
microscopy, because those transformations affect magnetic properties. Then, these 
particles were dispersed in epoxy matrices in order to spatially separate individual particles. 
The magnetic properties of ZFNPs and ZFMBs were investigated using various magnetic 
measurement techniques, including hysteresis curve, zero-field/field cooled magnetization, 
and remanence measurements. This chapter aims to understand the influence of the 
different arrangements of nanoparticles on magnetic properties, which can open interesting 
perspectives in controlling magnetic behavior via magnetic interactions, as well as in 







3.2 Experimental Section 
3.2.1 Materials 
Iron acetylacetonate (Fe(acac)3), zinc acetylacetonate (Zn(acac)2), oleylamine, 
ethylene glycol, benzyl ether, and chloroform were purchased from Acros organics (USA). 
Oleic acid was acquired from Alfa Aesar (USA). Poly(vinylpyrrolidone) (PVP, MW ~50 
kDa) and dodecyltrimethylammonium bromide (DTAB) were obtained from Sigma 
Aldrich (USA). Ethanol (200 proof) was purchased from DeconLab (USA). 
 
3.2.2 Synthesis of Zinc Ferrite Nanoparticles 
Zinc ferrite nanoparticles (ZFNPs) were synthesized by thermal decomposition. 
Briefly, 1.3 mmol Fe(acac)3, 0.3 mmol Zn(acac)2, 2.1 mL of neat oleic acid, and 2.1 mL of 
oleylamine were added to 20 mL of benzyl ether and refluxed at 290 ˚ C for 1 h in a nitrogen 
atmosphere. The as-synthesized particles were precipitated by the addition of ethanol, and 
then thoroughly rinsed with the mixture of hexane and acetone (1:3 v/v) by centrifugation 
(5500g for 30 min). The rinsing procedure was repeated twice. The particles were dried 
under vacuum and resuspended in chloroform at ~20 mg/mL. 
 
3.2.3 Synthesis of Colloidal Assemblies of ZFNPs 
The colloidal assemblies of ZFNPs (ZFMBs) were prepared using a 
microemulsion/evaporation technique. First, 1.0 mL DTAB solution (20 mg/mL) was 





vortexed for 5 min. Then, the emulsion was transferred to a round bottom flask and the 
chloroform was selectively removed by placing the flask in a water bath (40 °C) and 
purging with nitrogen. The resulting aqueous solution was injected into a flask containing 
5 mL of PVP in ethylene glycol (110 mg/mL) under vigorous stirring. After stirring for 10 
min at room temperature, the mixture was heated to 80 °C, refluxed for 6 h under an inert 
atmosphere, and was cooled to room temperature. Subsequently, the colloidal assemblies 
of ZFNPs were separated by centrifugation (5500g, 10 min) and the black precipitate was 
resuspended in 15 mL of ethanol. This centrifugation was repeated twice. Finally, the 
particles were resuspended in 10 mL of ethanol. 
 
3.2.4 Characterization 
3.2.4.1 Scanning (SEM) and transmission electron microscopy (TEM). SEM images 
were acquired using a Hitachi S-4800 (Japan), which was equipped with an energy 
dispersive X-ray spectroscopy module (EDS, INCA Inc.). Particle samples were drop 
casted onto a 1×1 cm silicon chip for SEM imaging and EDS analysis. TEM images were 
obtained using a JEM-2800 electron microscope (JEOL) operating at 200 kV. A drop of 
particle suspension was deposited on a lacey-carbon copper TEM grid and allowed to 
evaporate. All images were captured using a Gatan ORIUS CCD camera. 
3.2.4.2 X-ray diffraction (XRD). Powder X-ray diffraction (Panalytical X’Pert X-ray 
diffractometer, Philips) was used for the determination of crystallinity and phases of the 
ZFNPs. Diffractogram was collected with Cu Kα radiation (λ = 0.154 nm) at 40 mA and 






3.2.4.3 Inductively coupled plasma mass spectroscopy (ICP-MS). The molar ratio of 
Zn to Fe in the as-synthesized ZFNPs was determined by inductively coupled plasma mass 
spectrometer (Agilent 7500ce). The ZFNPs were dissolved in 3 mL HCl and 1 mL HNO3 
and diluted with 5% HNO3. A calibration solution containing 200 ppm Fe and 10.0 ppm 
Zn was prepared using single element standard solutions (Inorganic Ventures). The sample 
and calibration solution were run together using a double-pass spray chamber, quartz 
injector, and platinum cones. The collision cell was flushed with He gas at a rate of 8 
mL/min in order to minimize 40Ar16O interference at mass 56. 
3.2.4.4 Raman spectroscopy. Raman spectra were collected using a DXR Raman 
microscope (Thermo Scientific). Particle samples were prepared by evaporating a droplet 
of the particle suspension onto a 1×1 cm gold chip. Spectra were collected using a laser 
with a wavelength of 633 nm, power of 7 mW (at sample), a 10 s exposure time, and a 
resolution of 1 cm-1. Raman spectrum for Fe3O4 was obtained for comparison purposes 
from the RRUFF database (RRUFF ID# R080025).25 
 
3.2.5 Magnetic Measurements 
The magnetic characterization of samples was performed using a vibrating sample 
magnetometer (VSM, Microsense EZ7). Samples were prepared by immobilizing particles 
in a polymer matrix (i.e., epoxy) to reduce the potential effects of dipolar interactions. All 
particle samples were dispersed in UV-curable epoxy matrices (less than 0.1 wt%), injected 







3.2.5.1 Hysteresis curve measurement. Hysteresis curves were measured using a 
VSM at several temperatures (100, 150, 200, 250, and 298 K) with a field range of −15 
kOe to +15 kOe. The magnetization curve from a blank sample (i.e., epoxy matrix and 
capsule) was subtracted from the magnetization curve from the particle sample in order to 
obtain correct magnetic parameters. 
3.2.5.2 ZFC/FC measurement. For the measurement of zero-field cooled/field cooled 
(ZFC/FC) magnetization curves, an applied field of 100 Oe was used. For the measurement 
of ZFC curves, the sample was first cooled to 80 K in the absence of an external H, and 
the net magnetization was then measured with a temperature sweep rate of 3 K/min. 
Measurements of FC curves were carried out after the ZFC measurements. FC 
magnetizations were recorded while the sample was cooled from 300 to 80 K at 100 Oe. 
3.2.5.3 Isothermal remanence magnetization (IRM)/Direct current demagnetization 
(DCD). Interparticle interactions were investigated by IRM and DCD. For IRM analysis, 
the samples were first brought to a demagnetized state by applying alternating magnetic 
fields with an AC demagnetization factor of 0.9. The next step applied a magnetic field of 
a given value and Mr was measured at H = 0. This cycle was repeated with increasing H 
(0 to +1,000 Oe). DCD measurements were performed in a similar fashion. For DCD 
analysis, the sample was first exposed to an H of –1,000 Oe and the Mr was recorded by 
increasing H in the opposite direction to +1,000 Oe. The data from IRM and DCD were 
used to create delta-m (𝛿𝛿𝑚𝑚) plots and irreversible susceptibility (χirr), which is the first 
derivative of DCD measurement (i.e., d𝑀𝑀𝐷𝐷𝐷𝐷𝐷𝐷/𝑑𝑑𝑑𝑑). 
For non-interacting single-domain ferromagnetic particles with uniaxial anisotropy, 





other by the Wohlfarth relation:26 
 
                                                 𝑚𝑚𝑑𝑑(𝑑𝑑) = (1 − 2𝑚𝑚𝑟𝑟(𝑑𝑑)) (3.1) 
 
where 𝑚𝑚𝑑𝑑  is the normalized remanent magnetization from the DCD measurement 
[MDCD(H)/MDCD(𝑑𝑑𝑠𝑠𝑠𝑠𝑠𝑠)] and 𝑚𝑚𝑟𝑟 is the normalized remanent magnetization from the IRM 
measurement [MIRM(H)/MIRM(𝑑𝑑𝑠𝑠𝑠𝑠𝑠𝑠)]. The 𝛿𝛿𝑚𝑚 curve is defined as the difference between 
two normalized remanent magnetizations.27 
 
                                           𝛿𝛿𝒎𝒎 = 𝑚𝑚𝑑𝑑(𝑑𝑑) − (1 − 2𝑚𝑚𝑟𝑟(𝑑𝑑)) 
 
(3.2) 
3.2.6 Particle Size Measurement 
 ImageJ, a public image processing program (National Institute of Health),28 can be 
used to calculate area, pixel value statistics, distances, and angles of user-defined selections. 
For the calculation of an average diameter of ZFNPs, the boundaries of particles in a SEM 
image were defined using a default threshold. Then, the surface surface area (S) of each 
boundary was calculated. Assuming that particles are spherical, the S is converted into a 
diameter (D) using the equation for surface area of a circle (𝑫𝑫 = �4𝑺𝑺/𝜋𝜋 ). For the 
calculation of an average diameter of ZFMBs, the diameters of individual ZFMBs were 









3.3 Results and Discussion 
The results from a series of morphological, structural, and compositional analyses 
of the two sets of particles are presented in Figure 3.1-3.4. Figure 3.1A shows an SEM 
micrograph for the ZFNPs. The image reveals that the ZFNPs have a faceted shape, with a 
size ranging from 6 to 17 nm. The average diameter from the measurement of a larger 
number of particles (n=550) was 11 ± 2 nm. A histogram of these data is given in Appendix 
B.  
The TEM image and its accompanying lattice fringe pattern of ZFNP are shown in 
Figure 3.1B. The lattice fringe pattern confirms the crystalline nature of the ZFNPs. 
Moreover, the lattice spacing of 1.72 Å matches that for the (422) crystalline plane of 
magnetite (Fe3O4).29 This result is supported by the XRD pattern for the ZFNPs in Figure 
3.2A. The Bragg reflections for the ZFNPs (blue) are in close correspondence to those for 
the reflection data for Fe3O4 (red) with an inverse spinel structure.30 
The Raman spectra in Figure 3.3 provide further evidence that the ZFNPs have the 




Figure 3.1 Synthesis and characterization of ZFNPs. (A) SEM and (B) TEM images of the 
as-synthesized ZFNPs. The inset in (B) is a high-resolution TEM image of a single ZFNP 







Figure 3.2 Elemental analysis of ZFNPs. (A) XRD pattern and (B) EDS spectrum of ZFNPs. 
The XRD pattern of ZFNPs matches to that of Fe3O4 obtained from the RRUFF database 
(ID# R080025). Note that a silicon peak at 1.74 keV arises from the substrate used for 
imaging. The determination of Zn and Fe content shown in the inset of (B) was obtained 
by ICP-MS.  
 
of Fe3O4 typically shows three predicted phonon bands at 306, 538 and 669 cm-1.31 As 
evident in Figure 3.3, the as-synthesized ZFNPs exhibit three of these phonon bands 
assigned to symmetric bending of O with respect to Fe (Eg) at 321 cm-1, asymmetric 
stretching of Fe and O (T2g) at 549 cm-1, and symmetric stretching of O along Fe−O bonds 
(A1g) at 672 cm-1.31 
The presence of Zn in the ZFNPs was confirmed by EDS and ICP-MS. Figure 3.2B 







Figure 3.3 Raman spectra of the ZFNPs and ZFMBs. Note that Raman 
spectrum of Fe3O4 was obtained from the RRUFF database (magnetite, 
RRUFFID# R080025). 
 
keV. These EDS data yield a mole ratio for Zn:Fe of 4.8 and 95.2. The Zn:Fe mole ratio 
was also measured by ICP-MS (see inset of Figure 3.2B) to be 5.1:94.9. The ZFNPs are 
therefore nonstoichiometric (i.e., ZnxFe3-xO4) with the composition of Zn0.15Fe2.85O4. In the 
inverse spinel structure of Fe3O4, the oxygen atoms are arranged in a closely packed face-
centered cubic structure. This results in two different sublattices for occupation of iron 
atoms (i.e., Fe2+ and Fe3+): (1) tetrahedral and (2) octahedral sites. In theory, the octahedral 
sites are shared by an equal number of Fe2+ and Fe3+ ions, while the tetrahedral sites are 
only occupied by Fe3+ ions.30 Given the strong similarity of inverse spinel structure of our 
ZFNPs to that of Fe3O4, the zinc ions (Zn2+) would therefore occupy the octahedral 
interstices. 
Colloidal assemblies of ZFNPs (i.e., ZFMB) were synthesized using the emulsion- 







Figure 3.4 Synthesis and characterization of ZFMBs. (A) SEM image and (B) TEM image 
of the as-synthesized ZFMBs. The inset is a high-resolution TEM image of the ZFMBs, 
revealing a lattice spacing distance of ZFNPs in the ZFMB.  
 
the as-synthesized ZFMBs have a spherical shape and an average diameter of 172 ± 42 
nm (n=250). Moreover, Figure 3.4B reveals that a single ZFMB consists of a large 
number of ZFNPs assembled into a spherical bead, and a lattice d-spacing of 2.52 Å in 
the ZFMB sample corresponds to the (311) plane of the inverse spinel structure of Fe3O4.  
Raman spectroscopy is an effective tool to distinguish different forms of iron oxides, 
such as magnetite (Fe3O4) and maghemite (γ-Fe2O3), and, therefore, was used to check for 
the possible oxidation of the surface atoms of ZFNPs and/or transformation of the 
crystallinity phase of ZFNPs due to the assembly process. As can be seen in Figure 3.3, the 
Raman spectrum of the ZFMBs is close to indistinguishable from that for the ZFNPs. That 
is, the same three phonon bands at 327, 549, and 672 cm-1 are evident in the spectrum of 
the ZFMBs and ZFNPs. In contrast, the Raman spectrum of γ-Fe2O3 (an oxidized form of 
Fe3O4) is characterized with three bands around 350, 500, and 700 cm-1.31-32 These 
signatures for γ-Fe2O3 are absent in the spectra of ZFNPs and ZFMBs in Figure 3.4. We 
therefore conclude that the assembly of ZFNPs into ZFMBs does not alter on the 





To investigate the magnetic properties of ZFNPs and ZFMBs, a number of 
magnetic measurements were carried out via VSM. First, the hysteresis curves of ZFNPs 
and ZFMBs shown in Figure 3.5 were acquired at several temperatures (100, 150, 200, 
250, and 298 K). These curves are used to compare the three key magnetic parameters (Ms, 
Hc, and Mr) at different temperatures. At a sufficiently high temperature, the hysteresis 
curve of a magnetic material matches that of the Langevin function.33 If the hysteresis 
curve follows the Langevin function, the magnetic material is paramagnetic (zero Hc and 
Mr). When this functional dependence is observed in ferromagnetic or ferrimagnetic 
nanoparticles, it is called superparamagnetic. In Figure 3.5, both particle samples showed 
superparamagnetism with immeasurable values for Hc and Mr at room temperature. As 
temperature decreases, Ms for both ZFNPs and ZFMBs increase. This is due to a reduction 
in the extent of thermal agitation (kBT) as temperature decreases. Thermal agitation 
randomly flips the magnetization of MNPs, preventing an alignment of magnetic moments. 




Figure 3.5 Temperature-dependent hysteresis curves of (A) ZFNPs and (B) ZFMBs. Note 
that Hc and Ms for both ZFNPs and ZFMBs increase with the decrease in temperature. Each 
magnetization curve was normalized using the highest Ms value for each particle, which 





magnetic moments of MNPs in the direction of H, which leads to an increase in Ms. 
Hc is also affected by a change in temperature. As shown in Figure 3.6, Hc for both 
ZFNPs and ZFMBs decreases with an increase in temperature. 4, 34 This decrease in Hc is 
also due to the increase in thermal agitation (kBT) that causes random changes in the 
orientation of magnetic moments in particles. The increase in kBT with temperature results 
in an increase in the relaxation rate of magnetic moments and, consequently, an increase 
in the random orientation of the moments in a given measurement time interval. At low 
temperatures, however, the relaxation rate decreases and eventually becomes slower than 
the time of a measurement. This results in a magnetic hysteretic behavior (i.e., the 
appearance of Hc and Mr). Note that the relaxation process in our samples includes only 
the coherent rotation of magnetic moments (i.e., Neel relaxation),35 since the measured 
samples were fixed in epoxy matrices. It is interesting to see in Figure 3.6 that the Hc values 




Figure 3.6 Temperature-dependent Hc of ZFNPs and ZFMBs, extracted 
from hysteresis curve measurements. Below 200 K, the difference in Hc 





enhancement in the ZFMBs to strong magnetic dipolar interactions. The ZFNPs and 
ZFMBs are spatially distributed in epoxy matrices. However, a large number of ZFNPs in 
a single ZFMB is closely packed in a confined space, which leads to strong magnetic 
dipolar interactions between the ZFNPs in a ZFMB. It is known that magnetic dipolar 
interactions for nanoparticle assemblies are much greater than those of individual 
nanoparticles, and anisotropic magnetic dipolar interactions (e.g., nanoparticles aligned in 
a chain or nanoparticles packed in cylindrical pores) result in a large enhancement in Hc.18, 
36 In our case, since the oil phase (chloroform) was evaporated in a magnetically stirred 
water bath, it is possible that, during the evaporation step, the ZFNPs were weakly 
magnetized, which may have resulted in a preferential easy axis orientation and an increase 
in anisotropy.37 
The blocking temperature (TB) of ZFNPs and ZFMBs were obtained by ZFC/FC 
magnetization measurements. In the ZFC measurement, the particle samples are cooled in 
the absence of an external H, which facilitates alignment of magnetic moments to their 
easy axis. This alignment is then fixed at a low temperature. As temperature is increased, 
the thermal energy releases the fixed (a.k.a., “blocked”) magnetic moments from their 
initial alignments and, subsequently, allows those moments to align with the magnetic 
field. Therefore, the net magnetization at the beginning of the ZFC curve increases with 
temperature. Finally, the ZFC magnetization reaches a maximum and then undergoes a 
decrease with increase in temperature. This maximum temperature is defined as the 
“blocking” temperature, TB .38 As shown in Figure 3.7, the TB of the ZFMBs (~215 K) is 
significantly higher than that of the ZFNPs (~106 K). This shift to a higher temperature 







Figure 3.7 Zero-field cooled/field cooled (ZFC/FC) magnetization curves for (A) ZFNPs 
and (B) ZFMBs immobilized in epoxy matrices. ZFC/FC curves were measured between 
80 and 300 K. The higher TB of ~215 K and the magnetization reduction below the TB in 
the FC curve for ZFMBs are indicative of strong interactions between the individual ZFNPs 
in the ZFMBs. 
 
enhanced by the assembly formation when compared to the ZFNPs. Given that there are 
no phase or crystal structure changes evident in the seed ZFNPs upon colloidal assembly,  
the origin of the TB shift is attributed to the strong dipole-dipole coupling taking place 
between neighboring ZFNPs when present in the ZFMBs. It is known that interparticle 
magnetic coupling can suppress the magnetic spin reversal due to thermal fluctuations and, 
therefore, increase the transition from ferromagnetism to superparamagnetism to a higher 
temperature.13, 22, 39-40 Increases in TB after the cluster/assembly formation have also been 
found in other systems.13, 22-23, 41 
The FC magnetization curves of ZFNPs and ZFMBs in Figure 3.7 (red) also convey 
information on the magnetic coupling between nanoparticles. As temperature decreases 
from 300 K in the presence of H, the net magnetization for both ZFNPs and ZFMBs 
increases. This behavior is due to a reduction in the thermal fluctuation of the magnetic 
moments as temperature decreases, leading to an increase in magnetization. However, there 





ZFMBs shows a maximum at ~200 K, while that of the ZFNPs continues to increase as 
temperature decreases. FC magnetization curves often have a plateau or a decrease below 
TB when strong dipolar interactions between MNPs stabilize magnetic spins in their initial 
configuration and blocks the spins from aligning with the field.14, 41-42 Therefore, the 
decrease in magnetization of the ZFMBs below ~200 K further indicates that there is a 
much stronger dipolar coupling between individual particles in the ZFMBs than with the 
ZFNPs.  
The magnetic interactions (i.e., types and strength of interaction) can be further 
examined using δm and irreversible susceptibility (χirr) plots based on IRM and DCD 
measurements. First, magnetic interactions were examined by δm plots (Figure 3.8A). A 
negative deviation from the non-interacting condition (gray linear line in Figure 3.8A) can 
be attributed to the dominance of magnetic dipolar interactions between particles, while a 
positive deviation arises from the exchange interactions between atoms at the surface of 
particles.27 Thus, the negative deviation in 𝛿𝛿𝒎𝒎 plots in Figure 3.8A shows that magnetic 




Figure 3.8 Investigation of magnetic interactions. (A) δm plot and (B) irreversible 
susceptibility (χirr) curves of ZFNPs and ZFMBs. The δm plot and χirr were derived from 





the value of 𝛿𝛿𝒎𝒎 value shifts from 35 Oe for the ZFNPs to 70 Oe for the ZFMBs. 𝛿𝛿𝒎𝒎 for 
the ZFMBs also reaches a more negative value and decays slower than ZFNPs. This implies 
that the higher anisotropic energy barrier of the ZFMBs, produced by the stronger dipole-
dipole interactions in ZFMBs, suppresses fast demagnetization of the ZFMBs. 
The field-dependent irreversible susceptibility (χirr) is related to the distribution of 
coercive fields (i.e., energy barrier distribution) in particle samples.8, 43 As shown in Figure 
3.8B, the χirr curve for the ZFMBs is broader than that for the ZFNPs, with the maximum 
shifting to a higher field. This indicates that the reversal processes of the magnetic moments 
in ZFMBs is slower than that of ZFNPs, which reflects a higher and broader energy barrier 
distribution in ZFMBs. It is known that magnetic dipolar interactions in nanoparticle 
assemblies are much stronger than that of individual MNPs and the magnetic dipolar 
interactions in the densely packed MNPs result in a ferromagnetic effect and coercivity 
enhancement.18, 22 Therefore, the formation of spherical assemblies induces an increase in 
the anisotropic energy barrier, leading to an increase in Hc. This observation is also 
consistent with a higher Hc for ZFMBs than that for ZFNPs in Figure 3.6.  
The present results in the previous magnetic measurements demonstrate that the 
magnetic dipolar interactions among ZFNPs in a single ZFMB is an extra source of 
anisotropy. This leads to enhancement in the thermal stability of magnetic moments of 
ZFNPs in the ZFMBs, which was observed in a larger increase of TB and Hc in ZFMBs. 
Increasing thermal stability of magnetic moments of MNPs (i.e., delaying the transition 
from ferromagnetism to superparamagnetism to a higher temperature) is an important 
research topic in magnetic recording area. Although the system discussed in this study does 





interesting aspect in terms of designing new magnetic materials via magnetic interactions. 
 
3.4 Conclusion 
Even though magnetic properties of nanomaterials are strongly dependent on their 
size and shape, magnetic interactions can also play a significant role in the magnetic 
properties of nanoparticles. The strength and nature of magnetic interactions depend on the 
arrangement of MNPs and their interparticle distance. In this chapter, we have investigated 
the influence of nanoparticle arrangement on magnetic properties by comparing two 
different particles. At room temperature, both ZFNPs and ZFMBs are superparamagnetic. 
Ms values for both ZFNPs and ZFMBs increase with a decrease in temperature. It is, 
however, interesting that the difference in Hc between ZFNPs and ZFMBs increases with 
a decrease in temperature. ZFC/FC magnetization curves indicated that TB of the ZFMBs 
is shifted to a higher temperature compared to that of the ZFNPs, indicating that the 
anisotropic energy barrier in the ZFMBs is increased. The increased energy barrier 
observed in the ZFMBs corresponds to a higher Hc of the ZFMBs than that of ZFNPs. 
Given that deformation of crystallinity and structure of ZFNPs upon assembly into ZFMBs 
has not been detected, as evidenced by TEM and Raman measurements, we believe that 
the arrangement of ZFNPs into spherical assemblies induces stronger magnetic dipolar 
interactions between the particles, which is responsible for the increase in the anisotropic 
energy barrier as well as Hc. This assertion is supported by IRM and DCD measurements, 
revealing that stronger magnetic dipolar interaction in the ZFMBs is present. 
In summary, this study shows that magnetic interparticle interactions are closely 





opens up the possibility for fine tuning magnetic properties. For example, while strong 
dipolar interaction in ZFMBs led to anisotropic energy barrier enhancement, ZFMBs still 
retain superparamagnetism, like ZFNPs, at room temperature. Since a single ZFMB 
consists of many individual ZFNPs, the magnetic moment of an individual ZFMB is on a 
par with a collective summation of magnetic moments of the individual ZFNPs clustered. 
Consequently, ZFMBs could be superior to individual MNPs for applications such as 
magnetic labels in biosensors, magnetically assisted drug delivery, and biomolecular 
separation. We believe that producing colloidal assemblies of MNPs could be an excellent 
way to develop new materials with desired magnetic properties for a specific application. 
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4.1 Introduction 
The design, synthesis, and surface functionalization of magnetic particles have been 
extensively researched due to their use in a number of technologies, including magnetic 
fluids,1 data storage,2 catalysis,3 bioseparations,4 biosensing,5 and in vivo/in vitro 
theranostics.6-7 With respect to the focus of this paper, magnetic particles are used as labels 
in solid-phase immunoassays that rely on magnetoresistive (MR) sensors for readout.8-10  
To serve as ideal labels, magnetic particles should have a high magnetic susceptibility, high 





coercivity. These particles should also be easily coated with antibodies and other molecular 
recognition element (MRE) to selectively tag the target analyte, while avoiding 
complications from aggregation and sedimentation.7, 11 These characteristics are directly 
linked to metrics of analytical performance, including sensitivity, specificity, limits of 
detection, dynamic range, and measurement reproducibility. 
There are two types of magnetic particles commonly used as labels: magnetic 
microbeads (µMBs) and magnetic nanoparticles (MNPs). µMBs consist of uniformly sized 
polymer spheres that are 1 to 5 µm in diameter and contain randomly dispersed nanometer-
sized magnetic crystals, typically iron oxides (15-35% by weight).9 Due to the large volume 
per µMB, a large m can be achieved, which translates to a large magnetic response. Values 
of m for µMBs typically range from 10-13 to 10-10 emu, and are much larger than those (≤ 
10-15 emu) of most MNPs.12-14 Furthermore, a number of µMBs exhibit superparamagnetic 
behavior, which indicates that the likelihood of magnetic-induced aggregation under 
ambient conditions is low.7 As a result, µMBs have been used in several studies on 
magnetic labeling and separations.15-17 However, the high mass of a µMB can result in their 
ballistic deposition onto an assay surface, leading to an excessive level of nonspecific 
adsorption.18-19 The large size of µMBs can also sterically screen neighboring binding sites 
on a capture surface, limiting the dynamic range of the assay.20 
MNPs, which typically range from 5 to 100 nm in diameter, are an alternative to 
µMBs. Most of the studied MNPs are iron oxide nanoparticles (IONPs) (e.g., Fe3O4 and γ-
Fe2O3), ferrites (e.g., MFe2O4, M = Co, Ni, Mn, and Zn), and metallic nanoparticles (e.g., 
Fe, Co, and alloys thereof).21 The size of MNPs more closely matches that of DNA, 





MNPs have a smaller m than µMBs, necessitating the use of a more sensitive detection 
system. There are two common approaches to increasing m of MNPs: increases in size and 
use of ferro- or ferrimagnetic materials. Larger MNPs have a larger m but have a size bound 
by the superparamagnetic limit (≤150 nm).21 Above this size limit, the magnetic 
interactions between MNPs are strong enough to cause aggregation. MNPs synthesized 
from ferro-/ferrimagnetic materials can also have a high m, but must be stabilized by 
surface coatings to combat strong magnetic interparticle coupling.23-24 
Our interest in this area stems from the use of nanoparticles as labels in a diagnostic 
tool for the detection of disease markers that is based on giant-magnetoresistance 
(GMR).25-29 In previous work, we demonstrated that streptavidin-coated µMBs 
(Dynabeads®) bound to biotinylated gold addresses can be quantitatively measured using 
a scanning GMR readout method which mimics that used for hard-disk drives.27-28 In our 
approach, the separation distance between assay substrate and GMR sensor is on the order 
of micrometers (10 to 50 µm)27, 30 as opposed to tens or hundreds of nanometers found in 
other GMR sensors.7-9, 12 Since the magnetic dipole field of magnetic particles decreases 
rapidly with distance (i.e., a decrease proportional to 1/r3, where r is the separation between 
particle and sensor),29 this architecture places a heavy emphasis on the use of MNP labels 
with a large m for low level detection. We have also found that the ballistic settling of 
µMBs can complicate the assay by inducing a larger level of nonspecifically adsorbed 
µMBs than that found with MNPs. As evident, the synthesis and design of 
superparamagnetic nanoparticle labels with a high m stand as an on-going need in order to 
realize effective magnetic labeling. 





colloidally assembled magnetic beads (Coll-MBs). By Coll-MBs, we are referring 
nanoparticle clusters that, when assembled together to form a larger particle, have a much 
higher m than that of the individual MNPs and remain superparamagnetic at the same 
time.31-37 Several different types of Coll-MBs have been successfully synthesized by using 
solvothermal methods,36, 38-39 amphiphilic polymer encapsulation,32 emulsion-based 
bottom-up assembly,31 and controlled induction of solvophobic interactions.37, 40 Among 
other methods, the emulsion-based assembly method allows to use small nanoparticles as 
building blocks and create larger particles to realize new physical/chemical properties for 
many applications. Recent work has shown the possibility of incorporating plasmonic or 
fluorescent nanoparticles into the assembly for use in magnetic resonance imaging agents, 
hyperthermic treatment, and other theranostic applications.32-33, 41 Most of the Coll-MBs 
synthesized to date are composed of IONPs,33-34, 41-42 which provides the opportunity for 
further increase in the m of Coll-MBs by using seed MNPs with a larger m. 
The work described herein takes an emulsion-based assembly tactic for the 
preparation of Coll-MBs with a higher m by using zinc ferrite nanoparticles (ZFNPs). To 
this end, ZFNPs, which have an inherently larger m than IONPs, were prepared via thermal 
decomposition and then used as seeds for forming colloidally assembled zinc ferrite 
magnetic beads (ZFMBs). The ZFMBs were subsequently functionalized with a layer of 
polyacrylic acid and conjugated with streptavidin by carbodiimide linking chemistry. The 
product at each step in the procedure was characterized by electron microscopy, energy-
dispersive X-ray spectroscopy, infrared spectroscopy, magnetometry, and dynamic light 
scattering. The streptavidinated ZFMBs were also compared to two streptavidinated 





and colloidal stability. Finally, the streptavidinated ZFMBs were used as magnetic labels 
in sandwich immunoassays for the detection of osteopontin (OPN), a potential pancreatic 
cancer marker, and compared assays carried out using Dynabeads. We believe that the 
approach and materials presented in this paper can potentially serve as the basis for a new 
class of superparamagnetic labels with a large m for magnetic immunoassays, as well as 
for other biological applications (e.g., magnetic separation and theranostics). 
 
4.2 Experimental Section 
4.2.1 Materials 
Iron acetylacetonate (Fe(acac)3), zinc acetylacetonate (Zn(acac)2), oleylamine, 
ethylene glycol, benzyl ether, and chloroform were acquired from Acros organics (USA). 
Oleic acid and poly(acrylic acid) (PAA, MW ~5.1 kDa) were purchased from Alfa Aesar 
(USA) and Fluka (Japan), respectively. Poly(vinylpyrrolidone) (PVP, MW ~50 kDa), 
poly(vinylalcohol) (PVA, MW 30−70 kDa), bovine serum albumin (BSA), sodium 
phosphate (monobasic and dibasic), 2-(N-morpholino)ethanesulfonic acid (MES), and 
dodecyltrimethylammonium bromide (DTAB) were obtained from Sigma Aldrich (USA). 
Streptavidin, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), N-
hydroxysuflosuccinimide (sulfo-NHS), dithiobis(succinimidyl propionate) (DSP), and 
modified Dulbecco’s phosphate-buffered saline packs (10 mM PBS) were acquired from 
Thermo Scientific (USA). Dynabeads® (Streptavidin, MyOne C1) and FITC-avidin were 
purchased from Invitrogen (USA). Streptavidin-conjugated Turbobeads® were obtained 
from TurboBeads (Switzerland). Monoclonal human osteopontin (OPN) antibody (Catalog 





no.1433-OP), and biotinylated polyclonal human OPN antibody (Catalog no. BAF1433) 
were acquired from R&D Systems (USA). Phosphate-buffered saline/casein block (5× 
concentrate) was purchased from Surmodics (USA). 
 
4.2.2 Synthesis of MNP Seeds 
ZFNPs and IONPs were synthesized by slight modifications to published 
procedures.43-44 For ZFNPs, 1.3 mmol Fe(acac)3, 0.3 mmol Zn(acac)2, and 2.1 mL of neat 
oleic acid and oleylamine were added to 20 mL of benzyl ether; this mixture was then 
refluxed at 290 ˚C for 1 h under an inert atmosphere. IONPs were synthesized by using the 
same set of conditions, but without Zn(acac)2. The resulting particles were then thoroughly 
cleaned with a mixture (3:1 v/v) of acetone and hexane by centrifugation (10200g and 10 
min) and drying under vacuum. The dried particles were resuspended in 5.0 mL chloroform 
at ~20 mg/mL. 
 
4.2.3 Synthesis of Coll-MBs of ZFNPs and IONPs 
The procedure of Cao et al. was modified for the synthesis of the Coll-MBs of 
ZFNPs and IONPs, as shown in Figure 4.1.37 Briefly, 1.0 mL of ZFNPs, suspended in 
chloroform, was added to 1.0 mL DTAB solution (aq., 20 mg/mL) in a 5 mL centrifuge 
tube and vortexed for 5 min. The emulsion was transferred to a round-bottom flask that 
was immersed in a 40 ˚ C water bath, and chloroform was removed by purging with nitrogen. 
The DTAB-stabilized Coll-MBs were then injected into another round bottom flask that 
contained 5.0 mL PVP solution (0.55 g PVP dissolved in 5.0 mL ethylene glycol), and this 






Figure 4.1 Schematic illustration of the synthesis of ZFMBs: (1) The oil-in-water emulsion 
was prepared by mixing ZFNPs with DTAB solution; (2) the oil phase was selectively 
evaporated; (3) DTAB-stabilized Coll-MBs coated with PVP; (4) refluxing at 80 °C for 6 
h; and (5) PAA layer deposition. 
 
The PVP-coated ZFMBs (ZFMBs@PVP) were centrifuged at 5500g for 30 min. Next, the 
precipitate was rinsed twice with ethanol, followed by centrifugation. The ZFMBs@PVP 
were resuspended in 10 mL EtOH at ~2 mg/mL. The same procedure was used in the 
synthesis of colloidal assemblies of IONPs (IOMBs@PVP). 
 
4.2.4 Polymer Coating and Streptavidin Conjugation 
The as-synthesized ZFMBs were also functionalized with a layer of PAA, followed 
by protein conjugation via carbodiimide linking chemistry. First, 0.5 mL of ZFMBs@PVP 
in ethanol were mixed with 1.0 mL of aqueous PAA solution (10 mg/mL). The mixture 
was sonicated for 10 min and mixed using an orbital mixer for 12 h. The PAA-coated 
ZFMBs (ZFMBs@PVP@PAA) were rinsed with deionized water (DI H2O) three times, 
followed each time by centrifugation and resuspension in 1.0 mL DI H2O. 
 Streptavidin conjugation was carried out using a two-step process with EDC/sulfo-





resuspended in 1.0 mL of 5 mM MES buffer (pH 6.5). EDC and sulfo-NHS solution (20 
and 10 mg/mL, respectively) were prepared in 25 mM MES buffer (pH 6.5 and 4 ˚C). 
ZFMBs@PVP@PAA were reacted by adding 50 μL EDC and 100 μL sulfo-NHS and 
incubating for 30 min at room temperature. The particles were then confined to the wall of 
the centrifuge tube using with a 1-cm3 neodymium magnet and the supernatant of unreacted 
EDC and sulfo-NHS was removed by decanting. This step was repeated once. The particles 
were then resuspended in 1.0 mL of 5 mM MES, followed by the addition of 60 μL 
streptavidin (2.5 mg/mL in DI H2O). This suspension was agitated for 2 h, and residual 
streptavidin was removed by centrifugation (2400g and 2 min). Finally, the 
streptavidinated ZFMBs (ZFMBs@PVP@PAA@SA) were suspended in 1.0 mL of 10 
mM phosphate buffer (pH 7.4) containing 70 mM NaCl and 0.2% (w/v) PVA as a blocking 
agent. 
 
4.2.5 Assay Substrate Design, MR Sensor Configuration, and Signal 
Analysis 
Detailed procedures for the fabrication of the assay substrate, the MR sensor 
configuration, substrate readout, and signal analysis are described in the Supporting 










4.2.6 Magnetic Sandwich Immunoassay for the Detection of a 
Potential Pancreatic Cancer Marker 
4.2.6.1 Immobilization of capture antibody. Assay substrates shown in Figure C1.1D 
were created using photolithographic and metal lift-off processes.27-28 Prior to the 
immobilization of the capture antibody, the substrates were etched in an oxygen plasma 
(Oxford 80 RIE) in order to remove residual photoresist. Etching was performed at 150 W 
for 6 min under 50 sccm O2. The substrates were then sonicated in acetone for 10 min, and 
rinsed with ethanol. The next step immersed the substrates in an ethanolic 1 mM DSP 
solution for 1 h to modify the Au addresses. After DSP modification, the substrates were 
rinsed with ethanol and dried with a stream of nitrogen. Next, a 40 µL droplet of 20 µg/mL 
monoclonal human OPN antibody in 10 mM phosphate-buffered saline (PBS, pH 7.4) was 
applied on top of each substrate and stored in a humidified chamber for 2 h. Subsequently, 
each substrate was transferred into a well of a 12-well plate and blocked with 1.0 mL of 
20% (v/v) casein blocking solution in PBS for 1 h to combat nonspecific adsorption. 
4.2.6.2 Antigen capture and labeling steps. A dilution series of recombinant human 
OPN (0, 0.5, 1.0, 5.0, 10, and 50 ng/mL) was prepared in 10 mM PBS and 1.0% BSA. 
These antigen solutions (1.0 mL each) were applied to separate capture substrates, allowed 
to incubate for 2 h, and rinsed with 10 mM PBS three times. The next step added 
biotinylated polyclonal human OPN detection antibody (0.5 µg/mL in 10 mM PBS 
containing 1.0% BSA) to each well, and then incubated for 2 h, and rinsed with 10 mM 
PBS three times. For labeling, a small droplet (40 μL) of magnetic label suspension was 
applied onto each substrate, fully covering the top of the substrate. The average 





and 7 × 1010 beads/mL, respectively, by using nanoparticle tracking analysis. The labeling 
step was allowed to continue for 1 h in a humidified chamber, and the unbound labels were 
subsequently rinsed three times with 5 mM borate buffer containing 150 mM NaCl, 
followed by a final rinse with DI H2O. 
 
4.3 Results and Discussion 
4.3.1 Synthesis and Characterization of Seed MNPs 
Most of the Coll-MBs studied to date were prepared using IONPs,31-33, 37, 40 which 
suggests the possibility to further increase in m by replacing IONPs with other MNPs of 
different composition. Recent work has shown that the magnetization of Fe3O4 
nanoparticles can be increased by introducing zinc in the interstices of the inverse spinel 
structure of Fe3O4.23, 45 This inspired us to explore the synthesis of ZFNPs as a means to 
create Coll-MBs with a high m. Shown in Figure 4.2A and Figure C.3 is electron 
micrographs of ZFNPs prepared as detailed in the experimental section. These ZFNPs 
shown in Figure 4.2A have an average diameter of 9.3 ± 1.6 nm. Most of the ZFNPs are 
spherical in shape, but some faceted ZFNPs are also evident upon closer inspection using 
TEM (Figure C.3). The EDS spectrum of as-synthesized ZFNPs (Figure C.3C) has the Kα 
and Lα peaks of Zn at 8.63 and 1.01 eV, respectively, which confirms the presence of Zn. 
An analysis of these EDS data yields a Zn:Fe molar ratio of 4.5:95.2 and agrees with the 
molar ratio determined by inductively coupled-plasma mass spectroscopy (ICP-MS)  
given in the inset of Figure C.3C (Zn:Fe = 5.5:94.5). 






Figure 4.2 (A) SEM image of as-synthesized ZFNPs. (B) Hysteresis curves of IONPs 
and ZFNPs, measured at room temperature. The inset presents hysteresis curves at 
low fields. 
 
superparamagnetic at room temperature (i.e., remanent magnetization and coercivity of 
both particles are essentially zero). As expected, the saturation magnetization (Ms) of 
ZFNPs (74 emu/g) is higher than that of IONPs (65 emu/g). The Ms value of our ZFNPs is 
comparable to those of MNPs of similar compositions, reported in literature.46-48 More 
importantly, the magnetization of ZFNPs (24.5 emu/g) is almost twice that of the IONPs 
(13.4 emu/g) at an applied field of 100 Oe, the magnetic field we use to carry out 
measurement with. 
 
4.3.2 Synthesis and Characterization of ZFMBs 
Colloidal assemblies of ZFNPs were synthesized as described in Figure 4.1. Briefly, 
an oil-in-water emulsion is produced by mixing ZFNPs in chloroform with DTAB solution. 
The selective evaporation of chloroform produces spherical assemblies of ZFNPs. The 
resulting assemblies are subsequently coated with PVP. By changing the amount of DTAB 
for a fixed concentration of ZFNPs, the average diameter of the ZFMBs can be tuned as 
shown in Figure C.4. The as-synthesized ZFMBs (i.e., ZFMBs@PVP) in Figure 4.3A are 






Figure 4.3 (A) TEM image of ZFMBs@PVP. Inset is a high resolution TEM image 
showing lattice spacing. (B) Image of as-synthesized ZFMBs obtained by using STEM 
mode. Scale bar is 100 nm. (C, D, and E) EDS mapping of ZFMBs@PVP, displaying 
the elemental distribution of oxygen, iron, and zinc. Scale bars are 100 nm. 
 
SEM images (Figure C.4). The TEM lattice fringes for the ZFNPs that make up the ZFMBs 
are clearly evident, as shown in the inset of Figure 4.3A; this indicates that the ZFNPs are 
crystalline with a d-spacing of 2.52 Å, which corresponds to the (311) plane of the inverse 
spinel structure of magnetite (Fe3O4).49  
ZFNPs. It is estimated that roughly 5,000 seed particles are clustered into a single 
assembly based on the average sizes of ZFNPs and ZFMBs (i.e., the volume of a single 
ZFMB is divided by that of a single ZFNP, assuming that no dead volume is present 
between ZFNPs in a ZFMB). The EDS maps of the ZFMBs in Figures 4.3C, D, and E 
confirm that Zn is present in the inverse spinel structure of ZFNPs. The packing of ZFNPs 
in these ZFMBs@PVP was examined by electron microscopy and electron diffraction 
studies (Figure C.5). Unlike the superparticles reported in literature,33-34, 37 the superlattice 
fringes of ZFNPs (like atomic lattice fringes) were not observed during SEM and TEM 





a ring-pattern rather than exhibiting single-crystal-like electron diffraction patterns (i.e., 
spots). We, therefore, conclude that ZFNPs are assembled randomly into a spherical bead 
rather than in an fcc superlattice of nanoparticles as has been found for other superparticles. 
The magnetic hysteresis curves for the two Coll-MBs (ZFMBs@PVP and 
IOMBs@PVP) in Figure 4.4 were measured at room temperature using VSM. The Ms of 
the ZFMBs@PVP (72 emu/g) is not significantly different from that of the ZFNPs (74 
emu/g). Over the field range of 100 to 150 Oe, the ZFMBs@PVP still demonstrate higher 
magnetization (21.5−27.4 emu/g) than IOMBs@PVP (9.3−12.7 emu/g) as shown in the 
inset of Figure 4.4. Interestingly, the ZFMBs@PVP remain superparamagnetic, which 
means that clustering of a large number of ZFNPs into a single ZFMB has little detectable 
impact on superparamagnetism of the individual particles at room temperature. More 
importantly the estimates in Table C.1 show that the ZFMBs have a much higher m (2.3 × 
10-13 emu/bead at 100 Oe) than that of a single ZFNP (5.4 × 10-17 emu/particle at 100 Oe); 










4.3.3 Functionalization of ZFMBs@PVP with a Layer of PAA 
The use of magnetic particles as labels relies on the ability of the labels to recognize 
and target an analyte of interest.11 Moreover, particles with smaller sizes are more 
colloidally stable and have a higher label density on a surface (i.e., a large number of labels 
bound on a surface), which leads to improved analytical sensitivity and dynamic range in 
an immunoassay.20, 50 Therefore, we examined the use of ZFMBs@PVP (average size of 
~160 nm) as magnetic labels, recognizing that there is always trade space between colloidal 
stability, the magnetic moment of magnetic labels, and assay performance. 
For this purpose, the particles were first coated with a layer of PAA by incubating 
ZFMBs@PVP in a PAA solution.23, 51 Evidence for deposition of PAA is presented by the 
IR spectra and ζ-potential measurements presented in Figure 4.5 and Figure 4.6A, 
respectively. A strong band at 580 cm−1 (not shown) was observed in all samples, and is 
associated with Fe−O phonon vibrations of the ZFNPs.52 The features between 1664−1645 
and 1462−1424 cm−1 in the ZFMBs@PVP spectrum are assigned to carbonyl (C=O) 
stretching mode of the pyrrolidone group and CH2 scissor mode, respectively, in the PVP 
coating.53 After PAA deposition, the presence of carboxylic acid was observed in 
theZFMBs@PVP@PAA spectrum: there are bands around 1413 cm−1 and 1710−1690 cm−1, 
which are symmetric carboxylate (COO−) stretching and carbonyl (C=O) stretching, 
respectively, of PAA.54 In addition, the negative ζ-potential value, shown in Figure 4.6A, 
of the ZFMBs@PVP@PAA at pH 6.5 results from deprotonation of the carboxylic acid 









Figure 4.5 IR spectra of ZFNPs, ZFMBs@PVP, and ZFMBs@PVP@PAA. 
 
 
Figure 4.6 (A) ζ-potential and (B) hydrodynamic size changes before and after streptavidin 
immobilization. Note that all particle samples for the measurement were suspended in 5 
mM MES (pH 6.5). 
 
4.3.4 Streptavidin Conjugation via Carbodiimide Chemistry 
Streptavidin (SA), a biotin-binding protein, was immobilized on 
ZFMBs@PVP@PAA by using carbodiimide chemistry (EDC and Sulfo-NHS). SA is 
frequently used as an MRE due to its high affinity for biotin with a dissociation constant 
(KD) in the range of 10-15 to 10-12 M.55-57 We found that when EDC was used together with 
sulfo-NHS, the activated ZFMBs@PVP@PAA was more colloidally stable compared to 
when only EDC was used; one-step carbodiimide chemistry (i.e., using EDC only) often 





presence of the negatively charged sulfonate group (SO3−) in sulfo-NHS which combats 
particle aggregation by electrostatic repulsion.58 
The conjugation of SA, a ~60 kDa tetramer, was characterized with DLS through 
changes in hydrodynamic sizes and ζ-potentials and by fluorescent microscopy. The ζ-
potential of suspended particles corresponds to the electrical potential at the slipping plane 
around the surface of the particles.59 As shown in Figure 4.6A, the ζ-potential of 
ZFMBs@PVP@PAA in 5 mM MES (pH 6.5) is −35 ± 1 mV. When SA was conjugated to 
the particles, the ζ-potential increases to −23 ± 1 mV. This change in ζ-potential is 
consistent with expectation based on the isoelectric point (pI ~6.5) of SA.60 The change in 
hydrodynamic size in Figure 4.6B also follows expectations. The hydrodynamic size of the 
ZFMBs@PVP@PAA increased ~15 nm after SA conjugation. This change is consistent 
with the molecular volume of SA, which is ~105 nm3.61  Lastly, bright green fluorescence 
(Figure C.6) was observed when ZFMBs@PVP@PAA were conjugated with FITC 
modified-avidin using the same conjugation procedure. Taken together, these results 
indicate that SA was successfully immobilized on the surface of ZFMBs@PVP@PAA. 
 
4.3.5 Comparison of Streptavidinated ZFMBs to Commercialized 
Magnetic Labels 
Prior to performing assays with our new particles, the magnetic properties and 
colloidal stability of the streptavidinated ZFMBs (i.e., ZFMBs@PVP@PAA@SA) were 
compared to two commercially available streptavidin-coated magnetic particles, 
Dynabeads and Turbobeads. Presented in Figure C.7 are SEM images for both particles. 





nanocrystals.62 Turbobeads are composed of ferromagnetic cobalt@carbon core-shell 
metallic MNPs with an average diameter of 30 nm.63-65 Magnetic hysteresis measurements 
in Figure 4.7A show that Turbobeads have high Mr and Hc (9.3 emu/g and 254 Oe, 
respectively) at room temperature, whereas the Dynabeads and ZFMBs@PVP@PAA@SA 
have both Hc and Mr near zero. The Ms values for the Dynabeads, Turbobeads, and 
ZFMBs@PVP@PAA@SA at a field of 15 kOe are 24, 45, and 67 emu/g, respectively. 
Note that our measured Ms for Turbobeads in Figure 4.7A is ~3× lower than that reported 
by the manufacturer (>150 emu/g). In conjunction with a recent report,66 we attribute this 
observation, at least in part, to oxide formation on the surface of the cobalt nanoparticles, 
which leads to a decrease in Ms. For magnetic label applications, a high m is more 
important than a high Ms. While having the lowest Ms among three label candidates, 
Dynabeads, due to the large size, have the highest m (6.8 × 10-12 emu/bead at 100 Oe) when 
compared to the ZFMBs and Turbobeads of 2.4 × 10-13 emu/bead and 2.8 × 10-16 
emu/particle, respectively (Table C.1). However, the steric hindrance from the larger size  
of Dynabeads can limit the number of labels that bind to a surface. This, in turn, affects the  
 
 
Figure 4.7 Comparison of (A) field-dependent magnetization, and (B) hydrodynamic 
size change of streptavidinated magnetic beads (Dynabeads, Turbobeads, and 
ZFMBs@PVP@PAA@SA). All particle samples for DLS measurement were 
suspended in 10 mM phosphate buffer at pH 7.4. Note that it was not possible to 





attainable dynamic range. 
To test colloidal stability, changes in the hydrodynamic size of the three magnetic 
labels were measured over 24 h by DLS. These results are presented in Figure 4.7B. The 
streptavidinated ZFMBs remained suspended over the entire 24 h period and held a 
constant hydrodynamic size, i.e., no detectable aggregation. The hydrodynamic size of the 
Dynabeads also remained unchanged at ~1100 nm for ~8 h, but then dramatically decreased 
to near zero over the next 7 h. This implies that Dynabeads settle much faster than the 
streptavidinated ZFMBs. Note that the sedimentation of the Dynabeads resulted in 
incorrect measurements of the hydrodynamic size after ~10 h. Lastly, we were unable to 
measure a change in the hydrodynamic size of the Turbobeads, which rapidly aggregated 
due to strong magnetic forces between these ferromagnetic particles. Indeed, the as-
received Turbobeads were aggregated upon arrival and they rapidly aggregated after 
sonication. Even when carrying out the very first measurement, the hydrodynamic size of 
the Turbobeads in Figure 4.7B is already much larger than its initial size. As a result, we 
only tested the utility of our streptavidinated ZFMBs and the Dynabeads as assay labels. 
 
4.3.6 Magnetic Immunoassays for the Detection of a Potential 
Pancreatic Cancer Marker 
To test the effectiveness of the Dynabeads and ZFMBs@PVP@PAA@SA, 
magnetic sandwich immunoassays for the detection of a potential pancreatic cancer marker, 
OPN, were carried out as illustrated in Figure 4.8 and analyzed using our MR sensor. 
Presented in Figure 4.9 is the resulting dose-response curves. An MR response of 







Figure 4.8 Schematic illustration of magnetic sandwich immunoassays: (A) Gold capture 
substrate preparation; (B) magnetic label preparation; and (C) major assay steps. The 




Figure 4.9 Dose-response curves of OPN assays performed with the Dynabeads and 
ZFMB labels. Each point represents the average of twelve MR responses from Au 
addresses in each substrate. The inset is the expanded dose-response curves at the 
concentration range of 0 to 5 ng/mL of OPN. 
 
indicates that a degree of nonspecific adsorption for both magnetic labels exists. The MR 
responses for Dynabeads and ZFMB labels appear to level off at ~20 and 50 ng/mL of 
OPN, respectively. As shown in Figures 4.9, C.8, and C.9, the response using Dynabeads 
increases with OPN concentration. Due to the higher m for the Dynabeads, the MR 
responses are greater than those from the ZFMB labels. However, the use of the Dynabeads 





dynamic range, and (2) a larger standard deviation in the MR responses. MR signals at the 
concentrations larger than 1 ng/mL then quickly increase, saturating at ~10 ng/mL. Similar 
dose-response curves with limited dynamic ranges have been observed when micron-sized 
beads were used as labels.20, 67 In addition, the MR responses are not differentiable due to 
the large standard deviations when the OPN concentration is less than 5.0 ng/mL. As shown 
in the inset of Figure 4.9, the MR response at 0.5 ng/mL of OPN is higher than that at 1.0 
ng/mL and shows a large standard deviation. This indicates that the number of the 
Dynabeads bound on assay surface significantly varies across address-to address (i.e., 
inconsistent labeling between the gold addresses exists). Due to these limitations of 
Dynabeads, a calculation of the theoretical limit of detection (LoD, a signal at blank plus 
3× standard deviation divided by the slope of the linear fit) was impossible. We speculate 
that a LoD is present between 5 to 10 ng/mL (80 to 160 pM) when the Dynabeads used as 
labels. 
On the other hand, the MR response of the assay labeled with the ZFMB labels 
gradually increases with a OPN concentration up to ~50 ng/mL, as evident in Figure 4.9, 
C.10, and C.11. The average MR responses from the streptavidinated ZFMBs are smaller 
than those observed for the Dynabeads at the same OPN concentration, which is due to the 
~30× lower m of the ZFMBs than that of the Dynabeads. However, MR responses increase 
with OPN concentration between 0 and 10 ng/mL; an OPN concentration less than 10 
ng/mL can be evidently differentiated from each other. In addition, the ZFMB labels appear 
to be more uniformly distributed across the addresses, which is reflected in the smaller 
standard deviations of MR responses at all OPN concentrations. Given that the MR 





pM) is calculated. The ZFMB labels, therefore, exhibit an improved detection limit for 
OPN and a wider linear dynamic range. De Palma et al. also reported that the performance 
of magnetic immunoassays in terms of dynamic range and analytical sensitivity can be 
improved by employing sub-micron sized magnetic labels.20, 67 
We believe that the limited dynamic range, higher detection limit, and higher 
measurement deviation in the MR responses associated with the Dynabeads can be 
attributed to three possible factors. First, the analytes bound on an assay surface are tagged 
by larger particles (Dynabeads), which is screening neighboring binding sites and, 
subsequently, has a negative impact on labeling.9, 20, 67 Second, the delivery of Dynabeads 
to the capture addresses is dominated by gravity-induced sedimentation, rather than by 
diffusion.18-19 Third, the larger viscous drag forces exerted on the Dynabeads during rinsing 
steps can possibly detach a portion of the labels from the assay surface and, consequently, 
increase the measurement deviation.59 
 
4.4 Conclusion 
Magnetic labels play a critical role in determining the reproducibility and sensitivity 
of magnetic immunoassays. We utilized emulsion-based synthetic procedure to prepare 
colloidal assemblies of ZFNPs with a high m and superior colloidal stability. The colloidal 
assemblies (i.e., ZFMBs@PVP) retain superparamagnetic, which prevents magnetically-
induced aggregation in suspension. The m of ZFMBs@PVP (2.4 × 10-13 emu/bead at 100 
Oe) is ~4,000× greater than their constituent ZFNPs (5.4 × 10-17 emu/particle at 100 Oe). 
The colloidal stability of the ZFMB labels is superior to the two commercial magnetic 





an immunoassay for the detection of OPN in buffer, regarding dynamic range, LoD, and 
surface binding. We expect that the colloidally assembled ZFMBs developed herein will 
find uses beyond immunoassay labels, particularly in biological and theranostic 
applications where high m, facile surface functionalization, and colloidal stability are 
needed.  
As presented in this paper, creating nanoparticle assembly may allow to find new 
materials with desired chemical and physical properties. We, therefore, believe that novel 
multifunctional nanoparticle assemblies with new physiochemical properties can be 
developed by co-assembling different types of nanoparticles (i.e., plasmonic, magnetic, 
and/or quantum dot nanoparticles). Currently, using the ZFMB labels and our MR sensor, 
we are working on the development of multiplexed immunoassays for the detection of 
potential pancreatic cancer markers in human serum. 
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DEVELOPMENT OF GMR-BASED IMMUNOASSAYS FOR 
POTENTIAL PANCREATIC CANCER MARKERS: 
TOWARDS THE SIMULTANEOUS DETECTION 
OF MULTIPLE BIOMARKERS 
 
5.1 Introduction 
 Despite the low prevalence (3.1%) of pancreatic ductal adenocarcinoma (PDAC) 
in new cancer diagnosis, PDAC has a high mortality rate (i.e., 5-year survival rate of 5-
8%), which makes it the fourth leading cause of cancer-related deaths for both men and 
women in the U.S.1-4 Moreover, and in spite of the significant advances in medical care 
(i.e., patient selection, surgical technique, and perioperative care), tumor resection is still 
the best curative option for PDAC. Effective resection requires the early stage detection of 
PDAC, which is linked to the likelihood of a more positive patient outcome.2 It has been 
shown, for example, that patients diagnosed at stage 1 have a longer survival than those 
diagnosed in stages 2-4.5 
Early diagnosis of PDAC, nonetheless, remains problematic because of several 
factors, including: (1) the asymptomatic development of the disease; (2) the lack of one or 
more markers with high diagnostic accuracy; and (3) the variation in markers expressed in 
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PDAC patients. At present, carbohydrate antigen 19-9 (CA 19-9) is the only marker 
recommended by the National Comprehensive Cancer Network (NCCN) with respect to 
the clinical diagnosis of PDAC, and its utility is limited to use as a recurrence marker.4 
Complications of diagnosis of PDAC using CA 19-9 arise because: (1) CA 19-9 is detected 
in only ~25% of PDAC patients6; (2) the level of CA 19-9 can be elevated by inflammatory 
processes such as pancreatitis2; and (3) ~10% of the healthy population in the U.S. are 
classified as nonsecretors and do not produce CA 19-9.7-9 Indeed, studies have shown that 
the utility of CA 19-9 in screening asymptomatic patients is of little value because the 
probability that subjects with a positive screening test truly have PDAC (i.e., positive 
predictive value) is less than 1%.10-11 Thus, the low specificity of CA 19-9 for PDAC can 
lead to high numbers of false-positive results which, subsequently, result in further 
investigation and an increase in medical expenses. 
It has been proposed that an appropriate panel of biomarkers for PDAC may 
increase sensitivity and specificity and, consequently, improve the early stage diagnosis of 
PDAC.12-13 There are, nonetheless, a number of obstacles to address when attempting to 
develop a panel to screen asymptomatic PDAC patients, including the lack of a validated 
set of markers that can be used in such a panel. However, recent reports have identified 
several potential biomarkers that can successfully discriminate between PDAC and 
controls.14-21 Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM-1) 
and osteopontin (OPN) showed an improvement in diagnostic accuracy when compared 
with CA 19-9 only.20-21 However, CEACAM-1 and OPN are unable to discriminate PDAC 
from pancreatitis. Matrix metallopeptidase 7 (MMP-7) is another potential marker that has 
successfully distinguished patients with PDAC against patients with chronic pancreatitis, 
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but no improvement in diagnostic accuracy was shown over CA 19-9 alone.19 Tissue 
inhibitor of  metallopeptidase 1 (TIMP-1) is a secreted protein upregulated in PDAC 
tumors.22-23 These results suggest that the levels of OPN, CEACAM-1, TIMP-1, and MMP-
7 may find utility in PDAC diagnosis. Again, while no single biomarker has been shown 
to accurately predict the presence of PDAC, screening multiple biomarkers in a panel may 
improve diagnostic accuracy.13, 24 A study examining a panel of CA 19-9, TIMP-1, and 
carcinoembryonic antigen exhibited improved diagnostic accuracy over CA 19-9 alone.24 
It has been also reported that any panel of 7 biomarkers, among 40 non-correlated 
biomarkers characterized individually with thresholds of 32% sensitivity and 95% 
specificity, would achieve a sensitivity and specificity of 99% for the diagnosis of PDAC.12 
As has been postulated, the ability to realize early diagnosis of PDAC may be made 
more probable by a multiplexed test that could readily be performed at regular intervals 
(i.e., annual checkups) for screening every individual. The most well studied in-vitro 
immunoassays is the enzyme-linked immunosorbent assay (ELISA), which is a plate-based 
assay routinely used in clinical laboratories. However, screening a panel of PDAC markers 
using ELISA requires a large sample volume, which leads to increase in cost. Among many 
potential in-vitro diagnostic platforms for the early diagnosis of cancer, magnetoresistive 
(MR)-based detection combined with protein immunoassays is a promising technique. The 
high sensitivity of MR sensors is based on a phenomenon called giant magnetoresistance 
(GMR), which describes the large resistance change that occurs upon exposure to a 
magnetic field.25 This high sensitivity of GMR sensors has been applied to the bioanalytical 
arena for the development of new diagnostic platforms over the past few years, with the 
first report in 1998 by a group at the Naval Research Laboratory.26 Since then, many 
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research groups reported the development of GMR sensors with high sensitivity.27-31 In 
addition, the GMR-based diagnostic platform is theoretically capable of simultaneous 
detection of a large number of analytes with small volumes of sample due to the advantage 
of a photolithographic fabrication technique.32-33 Our group has developed a GMR-based 
detection system that separates the GMR sensor from the immunoassay substrate in a 
manner that imitates the working mechanism of hard disk drive readers.34-36 Our approach, 
while taking advantage of chip-scale immunoassays with a small sample volume, also 
allows for reuse of the sensor, which potentially reduces costs. 
Herein, we introduce the development of immunoassays for the detection of 
potential PDAC markers based on GMR sensor readout with in-house magnetic labels. We 
have shown that colloidally assembled magnetic beads are superparamagnetic, have a high 
magnetic moment, and can be employed as magnetic labels for our GMR sensor. First, 
immunoassays for four potential PDAC markers (i.e., OPN, CEACAM-1, TIMP-1, and 
MMP-7) were developed in buffer. Furthermore, the cross-reactivity between these 
markers was also tested in buffer. To emulate GMR-based detection for patient diagnosis 
of PDAC, immunoassays and cross reactivity studies of OPN and MMP-7 spiked in human 
serum were also investigated. We believe that the findings described in this paper show a 
promise toward the development of a GMR-based detection platform for the early 







5.2 Experimental Section 
5.2.1 Materials 
Iron acetylacetonate (Fe(acac)3), zinc acetylacetonate (Zn(acac)2), oleylamine, 
ethylene glycol, benzyl ether, and chloroform were purchased from Acros Organics (USA). 
Oleic acid and poly(acrylic acid) (PAA, MW ~15 kDa) were acquired from Alfa Aesar 
(USA) and Fluka (Japan), respectively. Poly(vinylpyrrolidone) (PVP, MW ~50 kDa), 
poly(vinylalcohol) (PVA, MW 30─70 kDa), bovine serum albumin (BSA), sodium 
phosphate (monobasic and dibasic), 2-(N-morpholino)ethanesulfonic acid (MES), and 
dodecyltrimethylammonium bromide (DTAB) were obtained from Sigma Aldrich (USA). 
Streptavidin, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), N-
hydroxysulfosuccinimide (sulfo-NHS), dithiobis(succinimidyl propionate) (DSP), and 
modified Dulbecco’s phosphate-buffered saline packages (10 mM PBS) were purchased 
from Fisher Scientific (USA). All antibodies and markers were acquired from R&D 
systems, Inc. (USA): monoclonal human osteopontin (OPN) antibody (catalog no. 
MAB1433), recombinant human OPN protein (catalog no.1433-OP), biotinylated 
polyclonal human OPN antibody (catalog no. BAF1433), monoclonal human (α-
CEACAM-1/CD66a) antibody (catalog no. MAB22441), recombinant human CEACAM-
1 (catalog no. 2244-CM-050), biotinylated polyclonal human CEACAM-1 antibody 
(catalog no. BAF2244), monoclonal human TIMP metallopeptidase inhibitor 1 (TIMP-1) 
antibody (catalog no. MAB970), recombinant human TIMP-1 (catalog no. 907-TM), 
biotinylated polyclonal human TIMP-1 antibody (catalog no. BAF970), Duoset human 
metallopeptidase 7 (MMP-7) antibody, Duoset MMP-7 standard, and biotinylated Duoset 
MMP-7 antibody. Phosphate-buffered saline/casein block was acquired from Surmodics 
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(USA). Pooled human serum (HE1532) was obtained from Randox (UK). 
 
5.2.2. Synthesis of Zinc Ferrite Nanoparticles and Zinc Ferrite 
Magnetic Beads 
Zinc ferrite nanoparticles (ZFNPs) were synthesized using a slight modification to 
a published procedure.37 For ZFNPs, 1.3 mmol Fe(acac)3, 0.3 mmol Zn(acac)2, 2.1 mL of 
neat oleic acid, and 2.1 mL of oleylamine were added to 20 mL of benzyl ether and refluxed 
at 290 ˚C for 1 h under an inert atmosphere. The as-synthesized ZFNPs were rinsed with a 
mixture (3:1 v/v) of acetone and hexane by centrifugation and dried under vacuum. The 
dried ZFNPs were resuspended in 5.0 mL of chloroform at a concentration of ~20 mg/mL. 
The colloidally assembled zinc ferrite magnetic beads (ZFMBs) were prepared by 
following a recent procedure.38-39 Briefly, 1.0 mL of ZFNPs in chloroform was added to 
1.0 mL of DTAB solution (20 mg/mL) in a 5 mL centrifuge tube. This mixture was 
thoroughly vortexed for 5 min and the emulsion was transferred to a round-bottom flask. 
Next, chloroform was removed by placing the flask in a 40 ˚C water bath and purging with 
nitrogen for 30 min. The DTAB-stabilized particles were then injected in 5.0 mL of PVP 
solution (0.55 g PVP dissolved in 5.0 mL ethylene glycol), magnetically stirred for 10 min, 
heated to 80 °C, and refluxed for 6 h under nitrogen. The PVP-coated ZFMBs were 
centrifuged at 5500g for 30 min and the pellet was then resuspended in 10 mL of ethanol. 
This rinsing procedure was repeated twice and the rinsed PVP-coated ZFMBs were 





5.2.3 Magnetic Label Preparation 
In order to conjugate molecular recognition moieties on the ZFMBs, the as-
synthesized ZFMBs were coated with a layer of PAA. First, 0.5 mL of ZFMBs in ethanol 
was mixed with 1.0 mL of aqueous PAA solution (10 mg/mL). The mixture was sonicated 
for 10 min and mixed over 12 h. The PAA-coated ZFMBs were rinsed three times by 
repeating centrifugation and resuspension in 1.0 mL deionized water (DI H2O).  
 Streptavidin conjugation was carried out using carbodiimide chemistry (i.e., 
EDC/sulfo-NHS). First, 1.0 mL of PAA-coated ZFMBs was centrifuged at 5200g for 3 min 
and resuspended in 1.0 mL of 5 mM MES buffer (pH 6.5). Then, 50 µL of EDC (20 mg/mL) 
and 100 µL of sulfo-NHS (10 mg/mL) in 25 mM MES buffer (pH 6.5) were added to the 
particle suspension. After 30 min, the particles were collected at the bottom of the 
centrifuge tube using a 1 cm3 neodymium magnet and the supernatant was discarded. The 
collected particles were resuspended in 1.0 mL 5 mM MES, followed by the addition of 60 
μL streptavidin (2.5 mg/mL in DI H2O). This suspension was agitated for 2 h on an orbital 
mixer. The unbound streptavidin was removed by centrifugation (2400g for 2 min). The 
streptavidin-conjugated ZFMBs were suspended in 1.0 mL of 10 mM phosphate buffer (pH 
7.4), which contained 70 mM NaCl and 0.2% (w/v) PVA to serve as a blocking agent. 
 
5.2.4 Characterization 
5.2.4.1 Scanning electron microscopy (SEM). SEM images of ZFMBs was obtained 
using SEM S4800 (Hitachi, Japan). A droplet of particle sample was drop casted on a 




5.2.4.2 Vibrating sample magnetometry (VSM). Hysteresis curves were acquired 
at room temperature using VSM EZ7 (Microsense, MA). 
5.2.4.3 Dynamic light scattering (DLS). A Zetasizer Nano (Malvern, United 
Kingdom) was used to measure a hydrodynamic size of ZFMBs. Three measurements per 
sample (n=3) were taken to determine an average value of hydrodynamic size. 
5.2.4.4 Optical microscopy. An optical microscope (BX50WI, Olympus, Japan) 
with 12.8 megapixel CCD camera (DP72) was used to capture assay substrates. 
 
5.2.5 Assay Substrate Configuration and Fabrication 
The assay substrate was fabricated using photolithography/lift-off techniques. 
Briefly, the assay substrates were created by evaporating nickel (10-nm thick) and gold 
(200-nm thick) addresses on Pyrex wafers (2-mm thick) after a layer of chromium (10-nm 
thick) was deposited as an adhesion layer. A titanium layer (15-nm thick) was deposited 
on the top of the nickel addresses to prevent oxidation. The wafer was then diced into 
individual 0.3 × 2.0 cm rectangular sticks (the substrate). The layout of the assay substrate 
is shown in Figure 5.1A and consists of twelve gold addresses interspersed between 
thirteen nickel addresses. The nickel and gold addresses are 200 × 200 μm in size. Each 
gold address is spaced (edge to edge) 500 μm from its neighboring nickel addresses. The 
nickel addresses are used as internal reference signals. The gold addresses are used for the 




Figure 5.1 Schematic illustration of assay substrate layout, assay procedure, and MR 
analysis. (A) Schematic design and actual photograph of assay substrate. (B) Assay 
procedure starting with capture antibody-modified assay substrate, followed by (1) antigen 
incubation, (2) detection antibody incubation, and (3) labeling step. (C) Depiction of assay 
substrate scanning. (D) MR signal analysis. 
 
5.2.6 Assay Procedure 
5.2.6.1 Immobilization of capture antibody. An overview of the assay procedure is 
given in Figure 5.1B. Any residual photoresist from the fabrication process on the assay 
substrate is removed by an oxygen plasma (Oxford 80 RIE). The substrates were cleaned 
at a power of 150 W for 6 min under O2 gas at 50 sccm. The substrates were then sonicated 
in acetone for 10 min, rinsed with methanol, and dried with nitrogen. The Au addresses 
were then functionalized by immersion in an ethanolic 1 mM DSP solution for 1 h. After 
DSP modification, the substrates were rinsed with ethanol and dried with nitrogen. Next, a 
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40 µL droplet of monoclonal human antibody (20 µg/mL) in 10 mM phosphate-buffered 
saline (PBS, pH 7.4) was applied to the top of each substrate, which was then stored in a 
humidified chamber. After 2 h, each substrate was transferred into a well of a 12-well plate 
and rinsed three times using 10 mM PBS. Then, the substrates were blocked by incubation 
with 1.0 mL of 20% (v/v) casein blocking solution in PBS for 1 h in a humidified chamber 
to combat nonspecific adsorption. 
5.2.6.2 Antigen capture and labeling steps. A dilution series (0.5 to 50 ng/mL) of each 
marker was prepared by spiking in 10 mM PBS containing 1.0% BSA. For serum assays, 
each marker was first spiked in neat serum, and then diluted using neat serum. Note that 
the concentration range for rh-MMP-7 is 0 to 10 ng/mL in both buffer and serum. For the 
preparation of calibration standards for rh-MMP-7 in diluted (1:4 v/v pooled human 
serum/PBS) serum, rh-MMP-7 antigen was first spiked in neat serum, and then diluted with 
PBS buffer in 1:4 v/v pooled human serum/PBS to obtain the desired concentration. These 
solutions were applied to the substrates in separate wells, incubated for 2 h in a humidified 
chamber, and rinsed three times with 10 mM PBS. In the next step, 1 mL of biotinylated 
polyclonal detection antibody (0.5 µg/mL in 10 mM PBS containing 1.0% BSA) was added 
to each well, incubated for 2 h in a humidified chamber, and rinsed with 10 mM PBS four 
times.  
For labeling, a droplet (~40 μL) of a magnetic label suspension was pipetted onto 
each coupon and incubated for 1 h in a humidified chamber. The average concentration of 
streptavidinated ZFMBs was estimated to be 7 × 1010 beads/mL by nanoparticle tracking 
analysis. Unbound labels were subsequently removed by rinsing four times with 5 mM 
borate buffer with 150 mM NaCl and finally washing once with DI H2O. 
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5.2.7 Cross Reactivity Studies 
For cross reactivity studies of the four markers (rh-OPN, rh-CEACAM-1, rh-TIMP-
1, and rh-MMP-7) in buffer, each assay substrate was divided into two sections by placing 
a thin strip of parafilm in the middle of the substrate; note that each section in a substrate 
has five gold addresses. The two sections of the substrate were then each modified with 
different capture antibodies by applying a 20 µL droplet of monoclonal human antibody 
(20 µg/mL) in 10 mM PBS (pH 7.4). Therefore, testing of each antigen required two assay 
substrates to accommodate the four sections modified with four capture antibodies of OPN, 
CEACAM-1, TIMP-1, and MMP-7. Subsequently, the two assay substrates were placed in 
a well of a 12-well plate and blocked with 1.0 mL of 20% (v/v) casein blocking solution in 
PBS for 1 h. Next, the two substrates were exposed to either a single antigen solution at 10 
ng/mL or a mixed antigen solution containing 10 ng/mL of each marker in PBS with 1% 
BSA, incubated for 2 h, and rinsed with 10 mM PBS three times. In the next step, 1 mL of 
a mixed detection antibody solution containing four detection antibodies (each at 0.5 
µg/mL in 10 mM PBS with 1.0% BSA) was added to each well, incubated for 2 h, and 
rinsed with 10 mM PBS four times. The labeling step was followed in the same manner 
described above. The cross reactivity studies in serum were pursued in a similar way to 
those in buffer, except with the preparation of antigen solutions in diluted serum (1:4 v/v 
pooled human serum:PBS). 
 
5.2.8 MR Data Analysis 
A completed assay substrate was placed above our MR sensor as shown in Figure 
5.1C. The separation distance (d) between the substrate and MR sensor was set at 10 ± 1.0 
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µm. To measure MR signals, the MR sensor was moved in the direction of x as shown in 
Figure 5.1C.  The translational scanning speed of our MR sensor along the addresses on 
the assay substrate was 31.1 ± 0.1 µm/sec under a magnetic field of 100 Oe. 
In order to quantitatively measure MR responses, we incorporate nickel addresses. 
The MR signals from nickel addresses not only account for any changes in d, but also 
enable normalization of the MR signal from each gold address. As described in Figure 
5.1D, the normalized response (MRnorm,i) from the i-th gold address with respect to the two 
adjacent Ni addresses can be written as follows, 
 
                    𝑴𝑴𝑴𝑴𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛,𝑖𝑖 = 2∆𝐸𝐸𝐴𝐴𝐴𝐴,𝑖𝑖∆𝐸𝐸𝑁𝑁𝑖𝑖,𝑖𝑖−1+∆𝐸𝐸𝑁𝑁𝑖𝑖,𝑖𝑖+1 (5.1) 
 
where ∆𝐸𝐸𝐴𝐴𝐴𝐴  and ∆𝐸𝐸𝑁𝑁𝑖𝑖  represent the MR responses of gold and nickel addresses, 
respectively. 
The MR response for each antigen concentration was obtained by averaging the 
MR responses from twelve replicates (gold addresses) in one substrate. Similarly, the 
standard deviation for each MR data point was determined from the twelve gold addresses 
on each substrate. 
 
 
5.3 Results and Discussion 
5.3.1 Magnetic Labels 
 
Before use as immunoassay labels, the colloidally assembled magnetic beads 





Figure 5.2 Characterization of as-synthesized ZFMBs. (A) SEM with the inset of 
hydrodynamic size of the as-synthesized ZFMBs. (B) Hysteresis curve at room temperature. 
 
of the as-synthesized spherical ZFMBs. Hydrodynamic diameter of the ZFMBs in the inset 
of Figure 5.2A, obtained by DLS, is 170 ± 56 nm, which agrees with the diameter of the 
ZFMBs determined from the SEM image (169 ± 36 nm, n=125). The hysteresis curve of 
the ZFMBs in Figure 5.2B indicates that the as-synthesized ZFMBs exhibit a remanent 
magnetization near zero at room temperature (i.e., superparamagnetism). Such a low level 
of residual magnetism ensures colloidal stability of the ZFMBs in suspension when 
prepared as labels. To use the ZFMBs as magnetic labels, ZFMBs were further coated with 
a PAA layer and, subsequently, conjugated with streptavidin via carbodiimide linking 
chemistry. 
The specific targeting ability of the streptavidinated ZFMBs for captured biotin 
molecules is shown in Figure 5.3, which contains images of the magnetic label-modified 
gold addresses after exposure to PBS and to a solution with rh-OPN at 10 ng/mL. Any 
binding on the gold address (Figure 5.3A) for the blank buffer sample is due to the 
nonspecific adsorption of ZFMB labels. The estimated surface coverage of the ZFMB 




Figure 5.3 Representative optical microscope images of gold addresses bound with 
ZFMB labels from OPN assays exposed to (A) 0 ng/mL and (B) 10 ng/mL of rh-OPN. 
Note that some nonspecific adsorption of ZFMB labels (red-circled) in (A) was 
observed in the blank. The scale bar for the insets is 10 µm. 
 
area of the address. At 10 ng/mL of rh-OPN, the increase in the amount of ZFMBs on the 
gold surface (Figure 5.3B) of ~50% of the total surface area reflects the more specific 
interaction between the captured antigens and recognition elements on magnetic labels. 
 
5.3.2 Detection of rh-OPN, rh-CEACAM-1, rh-TIMP-1, and rh-
MMP-7 Spiked in PBS 
Immunoassays for the detection of four potential PDAC markers (rh-OPN, rh-
CEACAM-1, rh-TIMP-1, and rh-MMP-7) were first developed and tested in buffer. Each 
assay was run as a singleplex. The dose response curves for the four markers spiked in 
PBS with 1% BSA are presented in Figure 5.4 as plots of MR response as a function of 
each marker concentration. In general, MR signals increase with the concentration of each 
marker. The blanks (i.e., 0 ng/mL) for each assay show a level of nonspecific binding (~3% 




Figure 5.4 Representative dose response curves for four potential PDAC 
markers in PBS. All markers were spiked in and diluted with PBS containing 
1% BSA. The immunoassay for each marker was performed singly. The 
resulting MR signals are the averages of MR responses from twelve gold 
addresses on each assay substrate. 
 
the blank plus three times the standard deviation of the blank and the slope (i.e., analytical 
sensitivity) from a least-squares linear fit of the responses up to 1 ng/mL. The LoDs for rh-
OPN, rh-CEACAM-1, rh-TIMP-1, and rh-MMP-7 spiked in buffer are calculated to be 240, 
190, 330, and 260 pg/mL (8, 5, 16, and 10 pM), respectively. These LoDs are lower than 
the clinically relevant cutoff levels in PDAC patients shown in Table 5.1 and, therefore, 






Table 5.1 The cutoff levels of rh-OPN, rh-CEACAM-1, rh-TIMP-1, and rh-MMP-7 in 
PDAC patients. In general, the cutoff values correspond to the mean level for the control 
groups (i.e., healthy control subjects and patients with chronic pancreatitis) plus two times 
the standard deviation of the mean level. Note that the mean levels of those markers in 
PDAC patients are higher than the cutoff values. All cutoff values were obtained using 
ELISA. 
Marker Method Cutoff Reference 
rh-OPN ELISA 25 ng/mL 1920 
rh-CEACAM-1 ELISA 4.8 ng/mL 2021 
rh-TIMP-1 ELISA 207 ng/mL 1516 
rh-MMP-7 ELISA 5.5 ng/mL 4240 
 
5.3.3 Cross Reactivity Studies for rh-OPN, rh-CEACAM-1, rh-
TIMP-1, and rh-MMP-7 Spiked in PBS 
Cross reactivity studies of the potential markers were performed both theoretically 
by Basic Local Alignment Search Tool (BLAST) analysis and experimentally by 
immunoassays in buffer. BLAST analysis is an algorithm for finding regions of similarity 
between biological sequences (e.g., amino acid sequences of nucleotides or proteins),41 
and, thus, was used to examine the similarities in the amino acid sequences of the potential 
PDAC markers to theoretically determine potential cross reactivity. The information on 
amino acid sequences for BLAST analysis was obtained from the National Center for 
Biotechnology Information (NCBI) database by using gene ID numbers of the markers 
provided from the vendor. Presented in Figure 5.5 is an example of BLAST analysis of rh-
OPN compared to rh-CEACAM-1, rh-TIMP-1, and rh-MMP-7. In Figure 5.5A, three blast 
hits of rh-OPN were found in rh-CEACAM-1 sequences (highlighted in yellow dashed 
box), but the alignment scores of the three hits are less than 40, indicating the similarities 





Figure 5.5 BLAST analysis of rh-OPN in comparison to (A) rh-CEACAM-1, (B) rh-
TIMP-1, and (C) rh-MMP-7. A query sequence of rh-OPN was compared with 
subject sequences of rh-CEACAM-1, rh-TIMP-1, and rh-MMP-7.  
 
are larger than 40. It should be noted that the alignment scores of possible combinations 
among the marker panel of rh-OPN, rh-CEACAM-1, rh-TIMP-1, and rh-MMP-7 had less 
than 40% similarity, which indicates that nonspecific binding of the markers to non-
complimentary antibodies is unlikely. 
Cross reactivity studies were also performed experimentally using immunoassays 
as depicted in Figure 5.6. A pair of two assay substrates had a total of four sections (each 
section containing a single antibody type) and was exposed to a sample containing either 
a single antigen or a mixed antigen solution that contained the four markers. Figure 5.7 





Figure 5.6 Schematic illustration of experimental cross reactivity study. (A) A pair 
of two assay substrates for cross reactivity study. Each substrate has two sections 
modified with two different capture antibodies. (B) Illustration of exposure of two 
substrates to a sample in a single well. (C) Description of assay substrate scanning 
and MR signal analysis. The signals labeled with asterisks represent MR responses 
from Au addresses modified with different capture antibodies. 
 
results of these cross reactivity studies, shown in Figure 5.7, match that from the theoretical 
results predicted in the BLAST analysis with little to no cross reactivity among all four 
markers. As shown in the first set of columns of Figure 5.7, when a pair of two assay 
substrates was exposed to rh-OPN only, the gold addresses modified with the capture 
antibody for rh-OPN gave a positive MR response larger than 5%. Other sections with 
nonspecific antibodies for rh-OPN showed ~3% in ΔMR. For the other markers, the same 




Figure 5.7 Cross reactivity studies of potential PDAC markers in 
PBS with 1% BSA. The marker concentration in all assays was 10 
ng/mL. Note that, for all substrates, the detection antibody solution 
is the mixture of biotinylated polyclonal antibodies for all markers 
at 0.5 µg/mL. Error bars represent average of MR responses from 
five gold addresses. 
 
nonspecific antibodies. When the mixed antigen solution (i.e., containing four markers) 
was applied to the assay substrate, MR responses from all gold addresses were clearly 
observed, which indicates that the presence of multiple markers may not prevent each 
marker from binding to its respective capture antibody. 
 
5.3.4 Detection of rh-OPN and rh-MMP-7 Spiked in Human Serum 
To simulate patient diagnosis, immunoassays were performed with the four 
antigens (i.e., rh-OPN, rh-CEACAM-1, rh-TIMP-1, and rh-MMP-7) spiked into neat 
human serum. Unfortunately, when rh-CEACAM-1 and rh-TIMP-1 are spiked in untreated 
human serum, the assays suffer from increased nonspecific adsorption of labels and low 




Figure 5.8 Dose response plots from ELISA for the detection of rh-CEACAM-1 and rh-
TIMP-1 in (A) neat and (B) treated serum. The inset in (B) shows responses with a 
least-squares linear fit at concentrations less than 1.0 ng/mL of rh-CEACAM-1 and rh-
TIMP-1. 
 
number of different scenarios, including interactions with heterophilic antibodies, human 
anti-mouse antibody, and complexation of markers with serum constituents.42-44 We 
suspect that the interference may arise from nonspecific interactions between endogenous 
heterophilic antibodies often found in human serum, and the capture and/or detection 
antibodies due to their poorly defined paratope regions.43-44 Heterophilic antibodies, which 
usually form a bridging set of linkages between capture and detection antibodies in 
sandwich immunoassays, can lead to high signals for samples due to an increase in 
nonspecific adsorption. The situation can also result in a decrease in analytical sensitivity 
due to the competition between an antigen and heterophilic antibody for binding sites on 
the immobilized capture antibody. 
To remove some of the proteins that may interfere with assay components, neat 
serum was treated with either a 100 or 50 kDa molecular-weight cutoff (MWCO) filter. 
The filtrate (i.e., the serum fluid containing serum components with molecular weights 
lower than the cutoff value of MWCO filters) was subsequently used for antigen dilution: 
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rh-CEACAM-1 and rh-TIMP-1 were spiked in the filtrates collected by MWCO 100K and 
50K, respectively. Dose response curves for rh-CEACAM-1 and rh-TIMP-1 in the neat 
and treated serum, obtained by ELISA, are shown in Figure 5.8. In neat serum (Figure 
5.8A), both assays suffer from a high level of nonspecific adsorption in the blank and no 
appreciable signal difference as a function of antigen concentration was observed. These 
results indicate the likelihood that serum proteins, which have molecular weights larger 
than the MWCO cutoff values, are interfering with assay components in the rh-CEACAM-
1 and rh-TIMP-1 assays. However, in the treated serum passed through the MWCO filters, 
dose response plots for rh-CEACAM-1 and rh-TIMP-1 were successfully obtained as 
shown in Figure 5.8B. It should be noted that, when rh-TIMP-1 spiked in the treated serum 
using MWCO 100K, the assay also suffered from poor analytical sensitivity due to the 
interference. This implies that rh-TIMP-1 may also interfere with serum components 
having a molecular weight between 50 and 100 kDa. 
While rh-OPN showed little to no change in assay performance when moving into 
human serum, rh-MMP-7 assays in neat serum showed a slight increase in nonspecific 
binding in a blank. As a result, MMP-7 assays were carried out in diluted serum. Figure 
5.9 shows the dose response plots of rh-OPN and rh-MMP-7 spiked in neat and diluted 
human serum (1:4 v/v pooled human serum:PBS), respectively. The LoDs of rh-OPN and 
rh-MMP-7, obtained from Figure 5.9, are 840 pg/mL (27 pM) and 500 pg/mL (18 pM), 
respectively. These LoDs are in the same order of magnitude with those obtained from 
samples spiked in PBS with 1% BSA, indicating that there is no significant complexation 
between assay components (i.e., capture antibodies and markers) and serum constituents. 




Figure 5.9 Dose response plots of rh-OPN and rh-MMP-7 spiked in neat 
and diluted serum (1:4 serum/PBS), respectively. The inset shows MR 
responses with a least-squares linear fit at concentrations less than 1.0 
ng/mL of rh-OPN and rh-MMP-7. Error bars represent average of MR 
responses from twelve gold addresses. 
 
serum : PBS), the relevant LoD of rh-MMP-7 in actual serum samples may increase to ~ 2 
ng/mL. More importantly, the LoDs for rh-OPN and rh-MMP-7 in serum are below the 
cutoff levels found in PDAC patients (Table 5.1). 
 
5.3.5 Cross Reactivity Studies of rh-OPN and rh-MMP-7 in Diluted 
Human Serum 
 Cross reactivity studies of rh-OPN and rh-MMP-7 in diluted human serum (1:4 v/v 
pooled human serum:PBS) were conducted in a fashion similar to those performed in buffer. 
Each marker was first spiked in neat serum and then diluted with PBS (1:4 v/v) to a 
concentration of 7.5 ng/mL. Figure 5.10 shows MR responses from duplexed assays of rh-
OPN and rh-MMP-7 at 7.5 ng/mL in diluted human serum. When the assay substrate was 
exposed only to rh-OPN, a large MR response arises from the addresses modified with α-




Figure 5.10 Cross reactivity of rh-OPN and rh-MMP-7 in diluted human serum 
(1:4 v/v pooled human serum:PBS). The final concentration of antigen 
solutions is 7.5 ng/mL after dilution. Error bars represent average of MR 
responses from five gold addresses. 
 
MMP-7, as shown in the first set of columns of Figure 5.10. This result shows that rh-OPN 
in serum selectively binds to its respective capture antibody (i.e., α-OPN) in the presence 
of α-MMP-7.   
However, rh-MMP-7 in diluted serum appears to bind to addresses modified with 
α-OPN and α-MMP-7. When the assay substrate with two capture antibodies for rh-OPN 
and rh-MMP-7 was exposed only to rh-MMP-7, the average MR response from gold 
addresses modified with the capture α-OPN was higher than that from gold addresses with 
α-MMP-7. Given that the cross reactivity study in buffer (Figure 5.7) showed minimal 
cross reactivity between these two markers, we suspect that other components in human 
serum interact with rh-MMP-7, which arises in the nonspecific binding of rh-MMP-7 to 
the capture antibodies of rh-OPN. Thus, the translation of these immunoassays to clinical 
diagnostics requires further understanding of fundamentals regarding interactions between 
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biomarkers, antibodies, and serum components. 
 
5.4 Conclusion 
Many studies have suggested that earlier diagnosis of PDAC is critical in improving 
patient outcomes. In order to accurately diagnose pancreatic cancer in its early stages, 
screening a panel of markers simultaneously from small serum samples is required. This 
chapter described efforts toward the development of GMR-based immunoassays for the 
simultaneous detection of potential PDAC markers (rh-OPN, rh-CEACAM-1, rh-TIMP-1, 
and rh-MMP-7). Using in-house magnetic labels, the dose response curves for all four 
PDAC markers gave LoDs in sub-nanogram per milliliter levels when spiked in PBS with 
1% BSA. Cross reactivity studies in buffer showed no significant interactions between the 
four markers, as predicted by the protein BLAST analysis. Upon dilution in untreated 
human serum, the dose response curves for rh-OPN and rh-MMP-7 gave LoDs of 840 and 
499 pg/mL in neat and diluted human serum, respectively, which are lower than the 
clinically relevant marker levels of rh-OPN and rh-MMP-7 in PDAC patients. However, 
cross reactivity studies of rh-OPN and rh-MMP-7 in human serum revealed that, while rh-
OPN does not show cross reactivity to MMP-7 capture antibody, rh-MMP-7 does bind 
nonspecifically to the OPN capture antibody, which limits the simultaneous detection of 
these markers in a sample. Thus, the detection of these markers in human serum poses 
some difficulties, such as possible complexation with unknown serum components. To this 
end, understanding the underlying biology in immunoassays (e.g., interaction between 
antibodies, antigens, and serum components) may be pivotal in translating this platform to 
a more clinically relevant setting. 
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Overall, we have shown that our GMR platform can simultaneously detect four 
markers in buffer at relevant clinical levels. With our current format for the assay substrate, 
our MR immunoassays can multiplex up to 12 different markers in principle, given the 12 
gold addresses present on each substrate. However, we anticipate that this format is easily 
scalable to hundreds of markers with the further development in the design of the assay 
substrate and GMR sensors. With the potential for high throughput and small required 
sample volumes, we foresee that this platform can be further used for new marker panel 
discovery and validation. Regardless, we believe that, with the improvement of biological 
aspects of immunoassays, a GMR-based diagnostic platform has great potential for early 
detection of disease in the clinical setting. 
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6.1 Research Overview 
 The development of a diagnostic platform for early disease detection remains 
challenging. This reflects the need to integrate a sensitive detection system, a panel of 
reliable disease markers, bioanalytical techniques, and effective labeling strategies. 
Furthermore, an effective diagnostic tool for early disease detection should have a short 
turnaround time, low cost, multiplexing capability, and processes for sample 
pretreatment/purification if needed. The recent progress and advancements in nanoparticle 
synthesis, microfabrication, and molecular diagnostics have enabled the development of 
novel diagnostic platforms for the detection of disease markers with increased performance, 
including a high level of sensitivity, rapid analysis, and multiplexing. Among many 
technologies, one such diagnostic tool is based on giant magnetoresistance (GMR). Due to 
its high sensitivity and potential in rapid and multiplexed detection, a GMR sensing device 
has shown promise in early detection of disease. This dissertation focused on the 
development of magnetic labels and their usage in GMR-based immunoassays, especially 
for the detection of potential pancreatic cancer markers. The body of this work included: 
(1) stabilization of magnetic nanoparticles (MNPs) using silica coating; (2) synthesis and 
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magnetic characterization of MNP assemblies; (3) preparation of magnetic labels with high 
magnetic moment (m) and colloidal stability using MNP assemblies; and (4) validation of 
the utility of GMR-based immunoassays for the simultaneous detection of potential 
pancreatic cancer markers. 
 Stable suspensions of MNPs with high m have widespread utility in biological 
applications. It is challenging, however, to stabilize ferro-/ferrimagnetic nanoparticles with 
high m in solution due to the strong magnetic forces that facilitate aggregation of the MNPs. 
Chapter 2 describes the preparation of stable, discrete silica-coated ferrimagnetic zinc 
ferrite nanocubes (ZFNCs) with high m. These results show that successful creation of 
discrete silica-coated ZFNCs is realized only after depositing multiple polyelectrolyte 
layers prior to silica coating. The intermediate polyelectrolyte layers play a significant role 
in preventing ZFNCs from aggregating during silica encapsulation. This encapsulation 
method can be implemented to easily prepare individual silica-coated MNPs with high m 
for use in various biological applications. 
 To use MNPs as labels in GMR-based immunoassays, the MNPs must be 
superparamagnetic and have a high m. In addition, the MNPs should be easily conjugated 
with molecular recognition elements to tag a specific target, while avoiding aggregation 
and sedimentation. Chapter 3 describes the fabrication of colloidal assembly of zinc ferrite 
nanoparticles (ZFNPs) to design a new magnetic material with superparamagnetism and a 
high m for label application. Furthermore, this chapter includes an investigation of the 
effect of nanoparticle assembly on magnetic properties. This study revealed that 
assembling ZFNPs into zinc ferrite magnetic beads (ZFMBs) led to an enhancement in the 
anisotropic energy barrier, due to an increase in the magnitude of magnetic dipolar 
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interactions. Interestingly, ZFMBs remain superparamagnetic at room temperature. More 
importantly, a single ZFMB can produce ~4,000 times larger m than that of a single ZFNP. 
This demonstrates the utility of superparamagnetic ZFMBs as magnetic labels for magnetic 
immunoassays. To this end, Chapter 4 describes the preparation of superparamagnetic 
ZFMB as magnetic labels. The primary steps for ZFMB labels consist of surface 
functionalization of ZFMBs with polyacrylic acid, and streptavidin conjugation via 
carbodiimide chemistry. The streptavidin ZFMBs are superior to commercially available 
magnetic beads (Dynabeads and Turbobeads) with respect to colloidal stability and assay 
performance. The work presented in Chapters 3 and 4 can be extended to other biological 
applications, where superparamagnetic particles with a high m and colloidal stability are 
needed. 
 Lastly, Chapter 5 focuses on the utilization of ZFMBs as magnetic labels in GMR-
based immunoassays for the detection of potential pancreatic cancer markers (rh-OPN, rh-
CEACAM-1, rh-TIMP-1, and rh-MMP-7). The immunoassays showed a sub-nanogram 
limit of detection for each marker spiked in buffer. Cross reactivity studies among these 
markers in buffer showed a low degree of cross reactivity among all markers, which 
corresponds with the results predicted by BLAST analysis. In addition, the limits of 
detection for rh-OPN and rh-MMP-7 in human serum was comparable to those of these 
markers in buffer solutions. Unfortunately, the remaining two markers, rh-CEACAM-1 
and rh-TIMP-1, showed assay interferences (i.e., low analytical sensitivity and high 
nonspecific adsorption in blanks) when spiked in human serum. Cross reactivity study of 
rh-OPN and rh-MMP-7 in human serum revealed that rh-MMP-7 nonspecifically binds to 
the OPN capture antibody, which hampered the simultaneous detection of rh-OPN and rh-
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MMP-7 in human serum. Nonetheless, along with the further understanding in biological 
aspects of immunoassays, this GMR-based diagnostic platform is believed to be a 
promising tool for multiplexed detection of disease markers.  
 
6.2 Future Directions 
 The development of a GMR-based multiplexing diagnostic platform for disease 
detection is an active and attractive subject in bioanalytical areas. Many ongoing and future 
efforts aim at translating the GMR-based detection platform to a point-of-care (PoC) 
format (i.e., rapid, field deployable, and easy to use). To realize a GMR-based PoC test, 
further optimization of magnetic labels, instrumentation, and assays would be needed, as 
described below. 
The development of MNP labels with a high m should be ongoing. As magnetic 
characteristics and target specificity of the labels are closely related to the performance of 
a GMR-based test, finding the optimal balance between magnetic characteristics and 
particle binding behavior would improve detection limits and aid in the utilization of a 
GMR-based detection system. 
 To realize a GMR-based PoC test, GMR instrumentation needs to become smaller 
to be more portable. Due to the advances in fabrication methods (e.g., microfabrication and 
lithography), it is anticipated that portable GMR systems may soon be available. 
Combining a GMR readout with paper-based immunoassays (e.g., lateral flow assays) may 
be a good candidate for rapid and field-deployable, GMR-based testing. 
 Most importantly, multiplexed detection of analytes, which remains a big hurdle 
for molecular diagnostics, should be extensively explored. To this end, understanding the 
138 
 
underlying biology in immunoassays (e.g., interactions between antibodies, antigens, and 
serum components) will be critical to achieving multiplexed detection and, subsequently, 




SUPPORTING INFORMATION FOR CHAPTER 2 
 
A.1. Experimental Details 
A.1.1. Dynamic Light Scattering (DLS) 
For hydrodynamic size measurements, the back-scattered mode was used at an 
angle of 174˚. Diffusion coefficients of MNP samples were obtained by fitting the 
correlation function with the cumulants analysis algorithm.1 The Stokes-Einstein 
equation was then utilized to convert the diffusion coefficient to the hydrodynamic 
diameter. The measurement duration was set to 2 min and three measurements were made 
for each sample to quantify measurement reproducibility. 
The Smoluchowski approximation was used to calculate the ζ-potential from the 






where η and ε are the viscosity and the dielectric constant of water (η = 0.8872 cP and ε 
= 78.5), respectively. The Smoluchowski approximation is applicable when the particle 
size is larger than the Debye length of the electrical double layer in a polar medium. The 
reported ζ-potential values are an average of three measurements per sample, where each 
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measurement is an average of 15 sub-runs. 
 
A.1.2. Remanent Magnetization Measurements 
The interparticle interactions of magnetic samples were investigated by IRM and 
DCD. For the IRM analysis, samples were ac-demagnetized and then exposed to a 
magnetic field (H). The remanence magnetization, MIRM(H), was measured at H = 0. This 
cycle was repeated by increasing H to the point in which the saturation field, HMAX, is 
reached (HMAX = 2,000 Oe for the ZFNC samples) and MIRM(H) is the correspoding 
saturation value, MIRM(∞). The DCD experiment was carried out in a similar manner, but 
the sample was first saturated at -HMAX and MDCD(H) was obtained by stepping H in the 
opposite direction to +HMAX. The MDCD(H) measured at field saturation is termed 
MDCD(∞). We note that HMAX is the field at which saturation magnetization, Ms, of the 
specimen is reached. 
The IRM and DCD data were used to construct Henkel and delta-m (𝛿𝛿𝛿𝛿) plots. 
These plots are generally used to examine the type and strength of interactions between 
magnetic particles. For an assembly of single-domain ferromagnetic particles with 
uniaxial anisotropy, the relationship between MIRM(H) and MDCD(H) is given by the 
Wohlfarth relation:2 
 
𝛿𝛿𝑑𝑑(𝐻𝐻) = (1 − 2𝛿𝛿𝑟𝑟(𝐻𝐻)) (A.2) 
 
where 𝛿𝛿𝑟𝑟  and 𝛿𝛿𝑑𝑑  denote the reduced terms of MIRM(H)/MIRM(∞) and 
MDCD(H)/MDCD(∞), respectively. A method to assess the type of interactions (e.g., dipole-
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dipole) between particles consists of plotting 𝛿𝛿𝑑𝑑(𝐻𝐻) vs. 𝛿𝛿𝑟𝑟(𝐻𝐻), the so-called Henkel 
plot.3 In an assembly of non-interacting particles, the Henkel slope is -2 and is termed the 
Wohlfarth line. Negative deviations from the Wohlfarth line indicate that demagnetizing 
interactions predominate the system (e.g., dipole-dipole interaction that stabilize the 
demagnetized state),4 while a positive deviation is attributed to interactions promoting a 
magnetized state (e.g., interparticle super-exchange interactions or RKKY-like 
coupling).5 In order to retain field information, a further term, 𝛿𝛿𝛿𝛿, was introduced into 
the relationship6 by Kelly et al.:  
 
𝛿𝛿𝛿𝛿 =  𝛿𝛿𝑑𝑑(𝐻𝐻) − (1 − 2𝛿𝛿𝑟𝑟(𝐻𝐻)) (A.3) 
 
where 𝛿𝛿𝛿𝛿 can conceptually be viewed to be twice the difference between the fraction of 
particles whose dipole orientation is switched at a particular field in IRM mode and DCD 
mode. 
 
A.2. Estimation of Magnetic Moment per Particle 
Virgin magnetic curves of demagnetized magnetic samples were measured by 
applying a magnetic field from 0 to 10,000 Oe. Figure A.5 is the representative virgin 
curve of the ZFNCs and Turbobeads®. It is assumed that the mass of surface capping 
molecules are negligible compared to that of the MNPs and the densities of the ZFNCs 
and Turbobeads are equal to those of bulk magnetite and cobalt. Basis for the calculation 
of magnetic moment per particle is 1 g of the sample. For example, the calculation of 
magnetic moment per particle of the ZFNCs is described below. 
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• Basis: 1 g of the MNPs 
• Average edge length of the MNPs: 129 nm = 1.29 × 10-5 cm 
• Volume of one cubic MNP 
𝑉𝑉𝑀𝑀𝑀𝑀𝑀𝑀 = 𝐿𝐿3 = (1.29×10−5)3 = 2.15 × 10−15 𝑐𝑐𝛿𝛿3/𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑐𝑐𝑝𝑝𝑝𝑝 
• Density of the MNPs: 5.175 cm3 
• Total volume of the basis (𝑉𝑉𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡): 0.193 cm3 
• The number of the ZNFCs in the basis 
𝑁𝑁𝑀𝑀𝑀𝑀𝑀𝑀,1𝑔𝑔 = 𝑉𝑉𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑉𝑉𝑀𝑀𝑀𝑀𝑀𝑀 = 0.193 𝑐𝑐𝛿𝛿32.15×10−15𝑐𝑐𝛿𝛿3/𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑐𝑐𝑝𝑝𝑝𝑝 = 9.00 ×1013 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑐𝑐𝑝𝑝𝑝𝑝𝑝𝑝 
• Magnetic moment of one MNP at 150 Oe 














Figure A.2. XRD diffractograms of as-synthesized ZFNCs and ZFNC@SiO2 
particles. Magnetite (Fe3O4) and zinc ferrite (ZnFe2O4) library diffractograms are 





Figure A.3. Particle size distributions from DLS 
measurement for (black) PEI-, (red) multiple 






Figure A.4. Hydrodynamic sizes of the silica-
coated ZFNCs. Prior to the silica coating, the 
ZFNCs had different number of polyelectrolyte 
layers; (black) 0, (green) 2, (red) 4, and (blue) 6 
layers. The size of silica-coated ZFNCs, 
appearing above 1000 nm, are due to large 
aggregates and/or the linear chaining of the 
ZFNCs when the seed ZFNCs are coated with 






Figure A.5. Virgin magnetic curves of 





Table A.1. Comparison of particle sizes measured using SEM and 
DLS. Note that the corner-to-corner length of particles was 
obtained by multiplying √3 to the edge length measured by SEM. 
 SEM DLS 
Size (nm) 𝒍𝒍 𝒍𝒍×√𝟑𝟑 Dh,int with FWHM 
PEI-coated 
ZFNCs 129 ± 15 224 ± 26 242 ± 80.2 
Polyelectrolyte-
coated ZFNCs N.A. N.A. 316 ± 120.1 
Silica-coated 




Table A.2. The magnetic moment per particle for different MNPs.  
































50 23 × 10-16 - 81 × 10-16 [7] 
Ademtech ADM03210 100 18 × 10-16 - 368 × 10-16 [7] 
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SUPPORTING INFORMATION FOR CHAPTER 4 
 
C.1. Experimental Details 
C.1.1. Assay Substrate Configuration and Fabrication 
The design and layout of the assay substrates, which consist of alternating nickel 
and gold addresses, are shown in Figure C.1D. Figure C.1D shows the entire substrate: 
twelve gold addresses are interspersed between thirteen nickel addresses. Both nickel and 
gold addresses are 200 × 200 μm in size. Each gold address is spaced (edge to edge) 500 
μm from its neighboring nickel addresses. The nickel and gold addresses are used for 
reference magnetic signals and assay areas, respectively.1-3 
The assay substrate was created using photolithographic and lift-off techniques. 
The detailed preparation of the assay substrate can be found elsewhere.1-3 Briefly, the 
assay substrates were fabricated by evaporating nickel (10-nm thick) and gold (200-nm 
thick) addresses on Pyrex wafers (2-mm thick). Prior to the evaporation of nickel and 
gold, a 10-nm thick chromium layer was deposited as an adhesion layer. To prevent 
possible oxidation of nickel addresses, a 15-nm thick titanium layer was overlaid on the 
nickel addresses. In the next step, the entire wafer was coated with parylene, which was 





individual 0.3 × 2.0 cm rectangular sticks (the substrate). 
 
C.1.2. MR Sensor and Station 
The MR sensor was provided by NVE Corp., the details of which have been 
described elsewhere, along with those for the magnetics test station.2-4  The sensor (Figure 
C.1C) is designed as an integrated circuit of four resistors in a Wheatstone bridge 
configuration. The two interdigitated resistors function as a sense pad (200 × 200 µm in 
size). The other two resistors act as reference resistors, which have 30-µm offsets from 
the sense pad. The MR sensors are coated with a 250-nm protective layer of silicon nitride 
(Si3N4). 
The MR station provides for relative motion between the assay substrate and MR 
sensor in the directions of x-, y- and z-axes as described in Figure C.2. For readout, the 
sensor was placed between two electromagnetic coils (Nicollet Technologies Corp., 
Minneapolis, MN) in a Helmholtz configuration. Once an assay substrate was placed 
inverted above the sensor, the separation distance (d, z-axis) between the sensor and assay 
substrate was adjusted by a four-phase stepper motor (STMicroelectronics L298N). 
Because the MR signal magnitude is dependent on d, it is critical to maintain a constant 
d throughout the substrate scanning. Also, the tilt angle of the assay substrate in the z-
axis was manipulated by an Oriel controller, which has a resolution of (2.0 ± 0.1) × 10-3 
degree per step, in order to prevent a change in d across the assay substrate while scanning. 
This process of changing the tilt angle was used to adjust the assay substrate until the 
plane of the substrate was parallel to the x-y plane of the MR sensor pad. Tilt in y-axis 





assay substrate in the x-axis was controlled by a micromanipulator (Model 6000, 
Micromanipulator Co., Carson City, NV) with a second four-stage stepper motor.  
 
C.1.3. MR Signal Analysis Method 
To measure MR signals, an applied field of 100 Oe was chosen after careful 
characterization of the transfer curve and noise of the MR sensor. The d between the 
substrate and MR sensor was set at 10 ± 1.0 µm. The translational scanning speed of the 
assay substrate along the addresses was 31.1 ± 0.1 µm/sec. 
In order to quantitatively measure MR responses, we incorporate magnetic 
reference addresses (i.e., nickel addresses).1-2 The MR signals from nickel addresses not 
only account for any change in d, but also provides for normalization of the MR signal 
from each gold address. As illustrated in Figure C.2B, the normalized response (MRnorm,i) 
from the ith gold address with respect to the two Ni addresses in closest proximity can be 
written as follows, 
 
𝑴𝑴𝑴𝑴𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛,𝑖𝑖 = 2∆𝐸𝐸𝐴𝐴𝐴𝐴,𝑖𝑖∆𝐸𝐸𝑁𝑁𝑖𝑖,𝑖𝑖−1 + ∆𝐸𝐸𝑁𝑁𝑖𝑖,𝑖𝑖+1 (B1.1) 
 
 
where ∆𝐸𝐸𝐴𝐴𝐴𝐴  and ∆𝐸𝐸𝑁𝑁𝑖𝑖  represent the responses (voltage changes) of gold and nickel 
addresses, respectively. 
The MR response for each antigen concentration was determined by averaging 
the MR responses from twelve replicates gold addresses on one substrate. Similarly, the 





on each substrate. 
 
C.1.4. Sample Characterization and Measurements 
Scanning electron microscope (SEM) images were collected using a Hitachi S-
4800 (Japan), which was equipped with an energy dispersive X-ray spectroscopy module 
(EDS, INCA Inc.). Particle samples were prepared by dropcasting onto a 1×1 cm silicon 
chip for SEM imaging and EDS. For transmission electron microscopy (TEM), samples 
were prepared by dropcasting onto a 3-mm lacey carbon grid and images were obtained 
using JEM-2800 (JEOL, Japan). For the estimation of average particle size, ImageJ was 
used and at least 250 particles were measured for each sample. 
Infrared (IR) transmission spectra were obtained using a Nicolet Magna 850 
Fourier transform IR spectrometer. The particle samples were dispersed in a KBr pellet 
at the concentration of ~1% (w/w). Spectra were collected using 512 scans at a resolution 
of 1 cm.-1 
Hydrodynamic size and zeta (ζ)-potential measurements were obtained by 
dynamic light scattering. A Zetasizer Nano (Malvern Instruments, United Kingdom) with 
a disposable folded capillary cell was used to measure the zeta (ζ)-potential and 
hydrodynamic sizes of the suspended particles. At least three measurements per sample 
(n=3) were taken to calculate average values of hydrodynamic size and ζ-potential. 
A system of nanoparticle tracking analysis (NanoSight LM10, Malvern 
Instruments, United Kingdom) was used to measure the concentration of magnetic labels. 
At least three aliquots per magnetic label were measured to estimate the average 





Magnetic hysteresis measurements were performed with a vibrating sample 
magnetometer (VSM EZ7, MicroSense, Lowell, MA) at room temperature. 
A fluorescent microscope (BX50WI, Olympus, Japan) equipped with a 
fluorescent cube (U-N41012) and a 12.8 megapixel CCD camera (DP72) was used to 
capture fluorescent images of FITC-avidin tagged ZFMB labels. A droplet of the FITC-
avidin tagged ZFMB labels was sandwiched between a microscope glass slide and cover 
slip for imaging. 
Inductively coupled plasma collision cell quadrupole mass spectrometer (Agilent 
7500ce) was used to determine the composition of Zn and Fe in the ZFNPs. Dried ZFNPs 
were digested in 3 mL concentrated HCl and 1 mL concentrated HNO3 (trace metal grade) 
and diluted with 5% HNO3 to about 200 ppb Fe and 10 ppb Zn. A calibration solution 
containing 200 ppb Fe and 10.0 ppb Zn was prepared using single element standard 
solutions (Inorganic Ventures). Diluted sample and calibration solution were run together 
using a double-pass spray chamber, quartz injector, and platinum cones. Collision cell 
flushed with He (8 mL/min) was used in order to decrease the 40Ar16O interference at 
mass 56. 
 
C.2. Estimation of Magnetic Moment per Particle 
To estimate magnetic moment per particle, mparticle, two main assumptions were 
used: (1) surface capping molecules are negligible; and (2) the densities of the ZFNPs, 
Turbobead®, and Dynabead® are equal to magnetite, cobalt, and the value given by the 
vendor, respectively. The mparticle is calculated based on 1 g of the sample. The calculation 





the Dynabeads provided by the vendor are 1.05 µm and 1.8 g/cm3, respectively. Assuming 
the particle is spherical, the volume per particle (Vparticle) is given by: 
 
𝑉𝑉𝑝𝑝𝑝𝑝𝑛𝑛𝑝𝑝𝑖𝑖𝑝𝑝𝑝𝑝𝑝𝑝 = 16𝜋𝜋𝐷𝐷3 = 6.06×10−12 𝑐𝑐𝑐𝑐3 (B1.2) 
 
Using the density, the mass per particle (Wparticle) can also be estimated as: 
 
𝑊𝑊𝑝𝑝𝑝𝑝𝑛𝑛𝑝𝑝𝑖𝑖𝑝𝑝𝑝𝑝𝑝𝑝 = 𝑉𝑉𝑝𝑝𝑝𝑝𝑛𝑛𝑝𝑝𝑖𝑖𝑝𝑝𝑝𝑝𝑝𝑝× 𝜌𝜌 = 1.09×10−12 𝑔𝑔 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑐𝑐𝑝𝑝𝑝𝑝⁄  (B1.3) 
 
The mass magnetization at 100 Oe (σs,100 Oe, emu/g) for Dynabeads, determined by our 
VSM, is 6.21. Therefore, the mparticle of Dynabead at 100 Oe can be obtained by 
multiplying Wparticle and σs,100 Oe: 
 
𝒎𝒎𝑝𝑝𝑝𝑝𝑛𝑛𝑝𝑝𝑖𝑖𝑝𝑝𝑝𝑝𝑝𝑝 = 𝑊𝑊𝑝𝑝𝑝𝑝𝑛𝑛𝑝𝑝𝑖𝑖𝑝𝑝𝑝𝑝𝑝𝑝×𝜎𝜎𝑠𝑠,100𝑂𝑂𝑝𝑝 = 6.77×10−12 𝑝𝑝𝑐𝑐𝑒𝑒 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑐𝑐𝑝𝑝𝑝𝑝⁄  (B1.4) 
 
The values of mparticle for the ZFNPs and ZFMBs were estimated in a similar fashion. For 
the mparticle for Turbobeads, the field-dependent magnetization (M-H curve) was obtained 







Figure C.1 MR station, MR sensor, and assay substrate.  (A) Image 
of actual MR station. Scale bar is 6 cm. (B) Image of MR sensor 
mounted on the green PCB board. The ink pen points to the sensor. 
Scale bar is 1 cm. (C) Image of MR sensor pad. The active sensing 
area is the square area in the middle. Scale bar is 200 µm. (D) 
Image of the assay substrate showing alternating nickel and gold 








Figure C.2 Schematic illustration of (A) substrate scanning above MR sensor, and (B) 






Table C.1 Calculation of mparticle. 
 
Particles mparticle at 100 Oe (emu/particle) 
Dynabeads 6.77 × 10-12 
Turbobeads 2.82 × 10-16 
ZFNP 5.35 × 10-17 








Figure C.3 TEM and elemental analysis of of the as-synthesized 
ZFNPs. High-resolution TEM image in (B) shows a lattice fringe 
pattern of the ZFNPs. EDS spectrum clearly shows the presence 
of Zn in the ZFNPs. The relative molar ratio of Zn to Fe in the as-
synthesized ZFNPs, confirmed by inductively coupled plasma 
mass spectroscopy (ICP-MS), is 5.5:94.5 with 1% precision. This 
result agrees well with that from the analysis of the EDS data: the 








Figure C.4 SEM images of as-synthesized ZFMBs with different sizes. The average 
diameters of (A) small and (B) large ZFMBs are 163 ± 46 and 378 ± 95 nm, 
respectively. Note that the average diameter was determined from SEM images by 
using ImageJ. The inset in (A) is a high-resolution SEM image, showing the 








Figure C.5 (A) TEM image and (B) electron diffraction pattern of the as-
synthesized ZFMBs. Note that the TEM image (A) was acquired under an 
objective-lens defocus and that the superlattice fringe pattern with other types 






Table C.2 IR peak positions and band assignments of ZFNP and ZFMB particles. 
 
Mode assignment Description Band position (cm−1) 
ν (Fe−O) ferrite Fe−O lattice vibration 580−590 
ν (C=O) carbonyl stretching in PVP 1631−1664 
δ (CH2) scissor bending in PVP, PAA, OA 1424−1462 
ν (C−N) carbon nitrogen stretching in PVP 1290 
νa (COO−) asymmetric carboxylate stretching in PAA 1560−1562 
νs (COO−) symmetric carboxylate stretching in PAA 1408−1413 
ν (C=O) carbonyl stretching in PAA 1690−1710 
νa (CH2) asymmetric methylene stretch 2920 








Figure C.6 Fluorescent microscope images of the ZMBs 
conjugated with fluorescent molecule-tagged avidin (FITC-
avidin). Scale bar is 20 µm. FITC-avidin molecules were 
conjugated to the ZFMBs@PVP@PAA using the same 
EDC/sulfo-NHS chemistry. A droplet of FITC-avidin 
conjugated ZFMBs in 5 mM MES (pH 6.5) was sandwiched 








Figure C.7 SEM images of commercially available 
streptavidinated magnetic beads: (A) Dynabeads and 
(B) Turbobeads. Dynabeads have a much higher 









Figure C.8 (A) Representative optical microscope images 
of gold addresses of OPN assays labeled with Dynabeads. 
Scale bar is 50 µm. (B) Average surface coverage of the 
Dynabeads as a function of OPN concentration. The 
average surface coverage was measured using ImageJ and 








Figure C.9 Representative MR signals of OPN assays labeled with Dynabeads. For 








Figure C.10 (A) Representative optical microscope 
images of gold addresses of OPN assays labeled with the 
streptavidinated ZFMBs. Scale bar is 50 µm. (B) Average 
surface coverage of the ZFMB labels as a function of 
OPN concentration. The average surface coverage was 









Figure C.11 Representative MR signals of OPN assays labeled with the 
streptavidinated ZFMBs. For simplicity, only two MR signals from gold addresses 
were plotted. Scale bar is 20 s. 
 
 
